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Abstract 
 
Neuroinflammation has a key role in the pathology of cognitive decline. This study 
sought to determine whether peripherally expressed inflammatory transcripts had 
significant associations with cognitive performance or cognitive decline, using genome-
wide and focussed candidate gene analyses.  
 
The study used data from 691 participants from the InCHIANTI study of ageing. 
Participants had undertaken Mini-Mental State Examinations at enrolment and at year 
9 of follow-up, and provided peripheral whole blood samples for RNA extraction at 
year 9. Global gene expression data was generated using the Illumina Human HT12 
BeadChip microarray. The study analysed global and inflammatory-focussed gene 
expression associations with cognitive performance and decline, and gene pathway 
associations with cognitive performance/decline. A candidate-driven RT-PCR 
expression quantitative trait locus (eQTL) analysis was also performed to determine 
whether genetic variants associated with cognitive decline affected gene expression 
abundance in association with phenotypic variation. 
 
Raised expression of a single transcript, C-C chemokine receptor 2 (CCR2), had a 
significant association with poor cognitive performance at global expression analysis 
and with both cognitive performance and cognitive decline in focussed inflammatory 
subset analysis. Expression of CCR2 in transgenic animals has previously been 
associated with both cortical Alzheimer disease pathology and peripheral vascular 
disease. eQTL analysis identified five significant eQTLs for local genes but no significant 
associations between peripheral expression of these genes and cognitive decline.  
 
This study’s analyses present little evidence that peripheral inflammatory gene 
expression is playing a significant role in cognitive impairment or preceding 9-year 
cognitive decline in this cohort. Only one inflammatory transcript (CCR2) was 
significantly associated with cognitive impairment at genome-wide analysis. The CCR2 
knockout mouse has been shown to have Alzheimer’s-like pathology; results of this 
study indicate that the mouse model may have relevance for the human population.  
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Chapter 1: Introduction 
1.1 Cognitive decline 
1.1.1 The impact of cognitive decline 
Cognitive function encompasses comprehension, language, memory, orientation, 
learning, adapting and reasoning. For most of adult life these functions remain stable 
but as individuals reach late middle-age, cognitive abilities can start to decline. 
Progressive age-related decline in cognitive function is experienced by more than 50% 
of adults over the age of 85 and dementia, which represents a stage of disabling 
cognitive decline, is estimated to affect 820,000 people in the UK (Luengo-Fernandez 
et al., 2010). It poses one of the great health threats of old age: cognitive decline 
causes significant social and functional loss, reduces quality of life, and increases 
individuals’ risk of institutionalisation and mortality (Luengo-Fernandez et al., 2010, 
Njegovan et al., 2001, Bennett et al., 2002).   
 
Worldwide, the prevalence of cognitive decline is predicted to quadruple in the next 
40 years (Brookmeyer et al., 2007). The total estimated worldwide costs of dementia 
were £380 billion in 2010, with about 70% of these costs occurring in Western Europe 
and North America (Wimo and Prince, 2010). The impact of cognitive decline on 
individuals, families, societies and health care systems is a large and increasing burden; 
socially and economically, the problem of providing sufficient medical, social and 
informal care for patients with disabling age-related cognitive impairment is ever 
growing (Harris et al., 2007). 
 
1.1.2 Cognitive decline is not simply a function of age 
Individuals differ in the trait of cognitive function throughout their lives, but cross-
sectional studies consistently report cognitive performance differences (particularly in 
recall) between older and younger individuals (Salthouse, 1994). Ageing affects all 
individuals’ cognitive function to different degrees, and the trajectory of cognitive 
change with age varies widely between individuals (Harris et al., 2007, Deary et al., 
2004). Cognitive decline is therefore an age-dependent process, but decline is not 
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simply a direct function of advancing age. Even among homogeneous populations, age-
related cognitive decline has a wide variety of phenotypes and clinical courses and 
results in anything from mostly inconsequential mild cognitive impairment to the 
accelerated and disabling cognitive decline associated with dementia syndromes 
(Payton, 2009).   
 
1.1.3 Cognitive decline is diagnosed functionally 
Multiple pathological processes contribute to cognitive decline (see section 1.2 for 
further information), but cognitive impairment and dementia are predominantly 
functional diagnoses. The two main categories of cognitive decline, representing two 
stages of cognitive change, are mild cognitive impairment and dementia. It is 
important to note that while these appear as distinct categories, the ageing brain is 
consistently prone to degeneration, making a degree of cognitive impairment “normal” 
in elderly populations (Deary et al., 2004). Cognitive decline (just like cognitive 
function) represents a spectrum of dysfunction (Morris and Price, 2001). The two 
categories described here are helpful in distinguishing functionally between normality 
and abnormality, and between different stages of this spectrum. 
 
1.1.3.1 Dementia 
Dementia can be defined as the development of multiple cognitive deficits that 
significantly impair an individual’s previous level of social and occupational function 
(Association, 2000). Various diagnostic criteria exist. The National Institute on Aging-
Alzheimer’s Association workgroup recommends that diagnosis is made based on 
evidence of cognitive or behavioural symptoms that:  
1. Interfere with the ability to function at work or at usual activities and 
2. Represent a decline from previous levels of functioning and performing and 
3. Are not explained by delirium or major psychiatric disorder  
 
Specifically, the group recommends that dementia diagnosis requires evidence of 
cognitive impairment in at least two of: memory, reasoning, judgment, language, 
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mood or behavior, and that diagnosis be made after thorough history-taking and 
objective cognitive assessment (McKhann et al., 2011). 
 
1.1.3.2 Mild cognitive impairment 
Mild cognitive impairment (MCI) represents a transitional stage of cognitive 
deterioration at which subtle cognitive defects impact on complex social and 
occupational activities, but individuals remain able to function normally in day-to-day 
tasks (Reisberg et al., 1982, Petersen et al., 1999). MCI, like, dementia, is a 
heterogeneous disorder with multiple aetiologies and varying presentations (Portet et 
al., 2006). MCI represents a risk state for dementia but, crucially, not all individuals 
with MCI progress to develop dementia (Wolf et al., 1998). The population prevalence 
estimates of MCI vary widely as a result of different classification criteria; Stephan et al 
(2008) identified prevalence estimates between 2.5% and 41% according to different 
trial criteria in their single population-based cohort (Stephan et al., 2008).  
 
1.1.4 Cognitive assessment 
Thorough history taking from individuals and carers is an essential prerequisite to the 
diagnosis of MCI or dementia. Physical examination, medication review and diagnostic 
imaging help to ensure that any modifiable cause for deterioration in cognitive 
function (such as medication, infection or focal pathology) is excluded before diagnosis 
is made.  
 
Cognitive impairment is screened for, and its progression monitored, with tests of 
global cognitive function, typically involving examination of memory, verbal 
comprehension, orientation and visuospatial ability. Neuropsychological testing of 
individual cognitive functional domains is the gold standard of cognitive function 
assessment, but is time consuming and requires specialist application (Zadikoff et al., 
2008). The most common clinically used test of cognitive function is the Mini-Mental 
State Examination (MMSE) © Psychological Assessment Resources, Inc., created by 
Folstein and Folstein (1975). 
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The Mini-Mental State Examination (MMSE) is an assessment of global cognitive 
function  widely used in both hospital and community settings as a dementia screening 
tool (Folstein et al., 1975, Mitchell, 2009). It is a sensitive and specific screening test 
for dementia in the general population (Houlihan et al., 2009). It is also used, less 
sensitively, as a diagnostic tool for mild cognitive impairment (Diniz et al., 2007).  As a 
widely available tool with which specialists and generalists are familiar, the MMSE 
provides a standardised examination of global cognitive function for use in the 
community and in specialised clinics (Folstein et al., 1975). It consists of a 30-point 
examination which takes around 10 minutes to complete, requiring verbal and written 
communication. The MMSE tests orientation, registration, attention and calculation, 
recall, and language. 
 
The MMSE has higher sensitivity and specificity than other common clinical tests of 
global cognitive function such as the Abbreviated Mental Test and the Mental Status 
Questionnaire (MacKenzie et al., 1996) as a dementia screening tool in the general 
population. However, the MMSE has limitations including a relative insensitivity to 
frontal-executive dysfunction and visuo-spatial deficits (Bak, 2007), and a significant 
ceiling effect  (Tombaugh and McIntyre, 1992). To minimise the impact of the MMSE’s 
functional insensitivities, individuals undergoing assessment by MMSE can 
concurrently undertake additional examinations e.g. Trail-Making Tests A and B, which 
assess visual scanning, numeric sequencing, visuomotor speed and frontal lobe 
function. These tests complement the measures quantified by the MMSE to give a 
more inclusive overview of individuals’ cognitive function and deficits. 
The ‘ceiling’ effect of the MMSE inhibits sensitive differentiation between medium and 
high cognitive performers, even when scores are corrected for educational level 
(Franco-Marina et al., 2010): high and moderate performers in other 
neuropsychological tests (often young individuals) typically score 29-30 points in the 
MMSE. This ceiling effect is far less prevalent in older adults, for whom MMSE scores 
typically drop below 28 points (Hobson and Meara, 1999).  
It is important to note that education, gender, social class and, crucially, hearing 
sensitivity all impact significantly on cognitive test scores (MacKenzie et al., 1996, 
Letenneur et al., 1999, Cullum et al., 2000). Individuals with high educational levels 
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have a greater cognitive reserve capacity as a result of early educational influence on 
their cognitive development, potentially allowing them to delay the manifestation of 
dementia symptoms longer than individuals with lower educational levels (Stern et al., 
1994). Any comparisons made between individuals’ MMSE scores must therefore take 
account of these potentially confounding factors. 
 
1.1.5 Leading causes of cognitive decline 
1.1.5.1 Late onset Alzheimer disease (AD) 
AD has an estimated prevalence of 13% among those 65 or older, and 43% of those 
aged 85 or older in the USA, according to the Alzheimer’s Association (Association, 
2011). Clinical criteria for diagnosis of AD are:  
1. core dementia symptoms (as described in section 1.1.3.1) and 
2. insidious symptom onset and 
3. evidence of progressive cognitive decline and  
4. specific cognitive changes indicative of one of the typical AD subcategories: 
amnestic or non-amnestic AD (McKhann et al., 2011) 
 
Amnestic AD is the more common presentation of the disease: patients exhibit 
prominent short-term memory and learning impairments. Expressive language, 
visuospatial or executive domain (e.g. judgment or reasoning) impairments are typical 
of non-amnestic AD (McKhann et al., 2011). Patients may demonstrate atypical courses 
of AD dementia, in which cases the diagnosis of “possible AD” is made. Further, the 
distinction between pure AD and mixed dementia is difficult to elucidate clinically. As a 
result, brain imaging and biomarker analysis have gained increasing credibility as 
diagnostic aids in patients demonstrating clinical changes of uncertain pathology. 
These tools, and their benefits, are introduced in section 1.3. 
 
1.1.5.2 Vascular dementia 
Vascular dementia is reported as prevalent in 8-15% of older adults with cognitive 
impairment, although as this figure discounts individuals who exhibit mixed dementia, 
true prevalence is most likely higher (Jellinger, 2008). Vascular dementia is diagnosed 
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clinically using criteria such as those issued by the National Institute of Neurological 
Disorders and Stroke and Association Internationale pour la Recherché et 
l’Enseignement en Neurosciences (NINDS-AIREN). Clinical diagnosis relies on:  
1. core dementia symptoms (described in section 1.1.3.1) and 
2. focal neurological signs consistent with stroke or evidence of cerebrovascular 
disease on brain imaging (CT/MRI) and  
3. an established relationship between cerebrovascular disease and dementia 
progression: either dementia onset within 3 months of stroke, or 
abrupt/stepwise deteriorations in cognitive function (Erkinjuntti, 1994).   
 
1.1.5.3 Dementia with Lewy Bodies 
Dementia with Lewy bodies (DLB) accounts for around 20% of dementia in the 
population (Aarsland et al., 2008). The spectrum of disorders with Lewy bodies also 
includes idiopathic Parkinson’s disease (PD) and Alzheimer disease with Lewy bodies. 
PD accounts for 3-4% of dementia in the population (Aarsland et al., 2005) and 
increases community-based individuals’ risk for dementia sixfold (Aarsland et al., 
2001). Clinical features indicating DLB or PD dementia are fluctuations in cognitive 
function and alertness, visual hallucinations and parkinsonian motor features: tremor, 
rigidity, bradykinesia and loss of postural reflexes. Sleep disruptions and depression 
are also supporting features (Hanson and Lippa, 2009).  
 
1.1.6 Known risk factors for cognitive decline 
Age is the biggest risk factor for cognitive decline: the majority of affected individuals 
receive their diagnosis after the age of 60 (Daviglus et al., 2010). However, cognitive 
decline progression is not simply a function of advancing age. Much attention has been 
paid to environmental, social and genetic factors that could additionally act as risk 
factors for cognitive decline in older adults.  
 
Systematic reviews of the available evidence report associations between dementia 
and high midlife total cholesterol, diabetes mellitus and obesity, as well as between AD 
and history of depression, current tobacco use and APOE ε4 status (Anstey et al., 
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2008b, Biessels et al., 2006, Beydoun et al., 2008, Kloppenborg et al., 2008, Ownby et 
al., 2006, Cataldo et al., 2010, Purnell et al., 2009).  Beyond these associations, sparse 
validated evidence exists for any other significant risk factors for cognitive decline, 
dementia or AD (Daviglus et al., 2010). 
 
1.1.7 Treatment for cognitive decline 
 
The mainstay of dementia treatment is acetylcholinesterase (AChe) inhibitor therapy. 
AChe inhibitors boost the cortical cholinergic pathways compromised by AD and DLB 
by increasing levels of acetylcholine in the brain. They ameliorate symptoms in 
patients with AD and DLB and are the only medical treatment shown to provide dose-
dependent improvement in patients’ cognitive function (McKeith et al., 2000, 
McGleenon et al., 1999). Critically, AChe inhibitors do not prevent, halt or reverse 
pathological progression of AD or DLB. Their provision, and the provision of any 
additional therapy e.g. antipsychotic medication, is focused on reducing or relieving 
individuals’ symptoms. 
 
Dementia is a devastating condition but there are currently major obstacles to the 
provision of therapeutic intervention. One obstacle is the recognition that pathological 
changes can precede clinical symptoms by over a decade. Functional cognitive decline 
is a late symptom of the biological deregulations causing cognitive impairment (Aisen 
et al., 2010, Amieva et al., 2005), meaning that at diagnosis of dementia, the processes 
responsible for its onset and progression are already well established. Treatment at 
the later, symptomatic stages of dementia may prove to be irrefutably unbeneficial 
(Aisen, 2010).  
 
To overcome this obstacle, recent evidence has presented a case for the use of 
biomarkers as tools in the pre-symptomatic diagnosis of dementia, particularly AD, to 
allow for interventional treatment and planning before patients become severely 
functionally impaired (fig. 1.1). The ultimate goal of this biomarker search is to identify 
asymptomatic individuals at high risk of dementia and to provide them with disease-
modifying treatments before dementia onset.  
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Figure 1.1 Current and future treatment of dementia syndromes. Taken from Cedazo-
Minguez et al. (2010), this theoretical figure illustrates cognitive function and its 
deterioration (y-axis) plotted against time (x-axis). The figure illustrates the late 
disease stage at which current biochemical and imaging markers can be identified, and 
current symptomatic treatments for dementia implemented. It also pictures the aims 
for the future: future markers would be identified and disease-modifying treatments 
provided early in disease progression.  
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1.2 Neuropathology of cognitive decline  
1.2.1 Neuropathological changes associated with ageing 
During ageing, brain neuronal loss is minimal in most cortical regions (Morrison and 
Hof, 1997), but cumulative oxidative damage to DNA, lipids and proteins, a decrease in 
antioxidants, and accumulation of neurotoxic products all result in loss of cell function 
(Payton, 2009). Synaptic changes (including loss of dendrites and dendritic spines) 
result in altered connectivity and less coordinated activation between cortical areas 
(Dickstein et al., 2007, Bishop et al., 2010). These features represent typical brain 
ageing. It is the border between healthy brain ageing and pathological brain ageing 
that has consistently represented a difficult line to draw; the crossing-point between 
“normal” and “abnormal” represents more of a continuum than a distinction in the 
brains of ageing individuals (Morris and Price, 2001). However, there are specific 
additional changes recognizable in the brains of individuals who demonstrate 
functional cognitive decline beyond that expected for their age. 
 
1.2.2 Neuropathological changes associated with cognitive decline 
The leading pathological cause of dementia is AD, which affects approximately 50% of 
adults aged 85 or over (Bishop et al., 2010). AD is characterized pathologically by the 
presence of extracellular insoluble β-amyloid peptide plaques and intraneuronal 
neurofibrillary tangles containing abnormally hyperphosphorylated tau protein, most 
notably in the entorhinal cortex and the CA1 field of the hippocampus (Clinton et al., 
2010). Imaging often reveals loss of volume in the medial temporal lobes of AD 
patients (Bishop et al., 2010). 
 
Beyond AD, the next most common cause of dementia is vascular dementia, then 
dementia with Lewy bodies (Bruandet et al., 2009). Rarer causes of cognitive decline in 
older people include fronto-temporal dementia, Parkinson’s disease and Huntington’s 
disease (Grossman et al., 2006). Significantly, “mixed dementia” is a common 
pathology, incorporating pathological features of both AD and vascular 
encephalopathy (Jellinger, 2008, Zekry and Gold, 2010). In autopsy studies, prevalence 
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estimates of mixed dementia pathology among individuals with clinical dementia range 
from 2-58% (Jellinger and Attems, 2007). 
 
The neuropathology of vascular dementia typically involves changes to both large and 
small vessels. Imaging findings which point to a diagnosis of probable vascular 
dementia include evidence of multiple large vessel infarcts or a single strategically 
placed infarct (e.g. in anterior or posterior cerebral artery territories, or the basal 
forebrain) (Erkinjuntti, 1994). Multifocal lesions visible on CT/MRI in patients with 
vascular dementia range from the diffuse microbleeds and microinfarcts of 
microangiopathy up to white matter lesions, hippocampal sclerosis and large infarcts, 
often associated with systemic arteriosclerosis (Jellinger, 2008, Vernooij et al., 2008).  
 
DLB is characterised pathologically by Lewy body deposits and gross atrophy, primarily 
in the substantia nigra and locus ceruleus (Kingsbury et al., 2010).  
 
1.2.3 Neuropathological processes common across dementia subtypes 
The clinical and pathological characteristics of specific dementia subtypes have been 
described above, but the cognitively declining brain rarely exhibits only one form of 
pathology. The clinical presentation of age-related cognitive decline is often the 
symptomatic end-point of many heterogeneous pathological processes, occurring after 
years of accumulated pathological changes have accrued (Jack et al., 2010). Current 
evidence suggests that the pathologies of cognitive decline described above are not 
independent pathways, but interdependent processes which promote each other’s 
development, and which are difficult to isolate from one another in the ageing brain 
(van Norden et al., 2011).  
 
One example of this concurrent pathological development is the multiple pathology 
associated with mixed dementia, which incorporates both cerebrovascular insult and 
AD changes. Beyond the simultaneous presence of the two processes, it is suggested 
that the two share common pathogenic mechanisms (Zhu et al., 2007). Indeed, it is 
probable that the multiple pathological pathways implicated in cognitive decline 
interact synergistically (Jellinger, 2008). Pathological features such as abnormal protein 
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aggregation, oxidative damage and neuroinflammation are common across multiple 
dementia syndromes (Halliwell, 2006). The next section describes these common 
pathways, highlighting their contribution to dementia syndromes and their synergistic 
interactions with other pathological processes. 
 
1.2.3.1 Neuropathology: protein aggregation  
β-amyloid 
Metabolism of β-amyloid (Aβ) and its precursor protein by β and γ-secretases is 
thought to be the primary trigger for the development of AD (Cosentino et al., 2010, 
Ertekin-Taner, 2010). Changes to the β-amyloid processing pathway result in 
overproduction or diminished clearance of the Aβ 42-residue isoform. Additional 
hydrophobic residues in Aβ42 make it more readily fibrillogenic than the more common 
Aβ40 isoform (Jarrett et al., 1993); accumulation of Aβ42 leads to Aβ self-aggregation 
into oligomers and fibrils, resulting in diffuse Aβ plaque formation in parenchyma and 
cerebral blood vessels (Yu et al., 2010, LaFerla, 2008). These plaques are neurotoxic: 
they stimulate inflammatory processes, act as potent synaptotoxins, enhance 
abnormal phosphorylation of proteins (including tau) and structurally alter fibrin clots, 
making them more resistant to degradation (Lorenzo and Yankner, 1994, Cortes-
Canteli et al., 2010, Ertekin-Taner, 2010).  
 
Tau 
Tau, a microtubule-associated axonal protein, is found to be hyperphosphorylated in 
AD. Hyperphosphorylation results in functional loss through disruption of tau’s role as 
an axonal transport regulator, relocalisation of tau protein from axons to the neuronal 
somatodendritic compartment, and toxic gain of function via production of toxic 
soluble tau (Iqbal et al., 2005). As a result, affected neurons undergo 
neurodegeneration, and hyperphosphorylated tau protein is packaged into 
neurofibrillary tau-containing tangles (Haass and Mandelkow, 2010). Tau appears to 
mediate Aβ toxicity when relocated to the somatodendritic compartment, although 
the mechanism of its influence remains unclear (Ittner et al., 2010). 
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α-synuclein 
Intraneuronal Lewy bodies and neurites are hallmarks of DLB and PD dementia, and 
are also prevalent in up to 60% of patients with AD (Kotzbauer et al., 2001). Their 
presence is associated with accelerated cognitive decline and a more aggressive course 
when associated with AD (Clinton et al., 2010). Lewy bodies and neurites contain 
aggregated α-synuclein, which normally functions as a presynaptic protein 
(Markesbery et al., 2009). α-synuclein aggregation may be induced by oxidative 
modification; the reduced ability of the ageing brain to clear misfolded proteins may 
also contribute to its accumulation. In common with tau protein, the α-synuclein found 
in Lewy bodies is hyperphosphorylated, potentially adding to its aggregative tendency 
(Ross and Poirier, 2004). 
 
There is evidence to suggest that β-amyloid, tau and α-synuclein may synergistically 
promote each other’s accumulation (Clinton et al., 2010). 
 
1.2.3.2 Neuropathology: oxidative stress 
Oxidative stress is postulated as one of the key contributors to cellular senescence 
(Harman, 1956). Oxidative damage from free radicals, including reactive oxygen 
species (ROS) produced by oxidative metabolism, cumulates in cells with increasing 
age, damaging proteins, lipids and DNA (both nuclear and mitochondrial) (Droge and 
Schipper, 2007). In the brain, high rates of oxidative metabolism are necessary to 
maintain intracellular ion homeostasis for signal propagation. The brain accounts for 
about 20% of basal O2 consumption and contains a high concentration of readily 
peroxidisable polyunsaturated fatty acids and a relative paucity of antioxidant systems. 
It is therefore particularly vulnerable to oxidative damage (Halliwell, 2001).  
 
Oxidative damage is more prevalent in the postmortem brains of individuals with mild 
cognitive impairment than controls (Keller et al., 2005), suggesting that oxidative 
damage occurs at higher levels in cognitive decline than in healthy patients. In 
addition, the neurodegenerative pathologies associated with dementia syndromes 
directly contribute additional oxidative stress to the ageing brain. The Aβ peptides of 
Alzheimer disease induce ROS production, and circuitously, oxidative stress can 
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increase levels of APP and increase β-secretase activity, triggering increased Aβ 
formation (Cai et al., 2011). Both intracellular hyperphosphorylated tau and 
extracellular Aβ oligomers trigger oxidative stress reactions (Pratico, 2008). Vascular 
dementia is associated with increased levels of vascular ROS, causing nitric oxide 
dysfunction and impairing endothelial barrier function (Lum and Roebuck, 2001, 
Bennett et al., 2009). In Parkinson’s disease, oxidative stress contributes directly to the 
degeneration of dopaminergic cells in the substantia nigra (Jenner, 2003).   
 
1.2.3.3 Neuropathology: neuroinflammation 
The central nervous system is in constant bidirectional communication with the 
immune system, and is monitored by innate immune surveillance, mediated by 
microglia and astrocytes (Di Filippo et al., 2008, Lue et al., 2010). This immune system 
becomes more reactive with advancing age: microglia become sensitised (“primed”) to 
exaggerated activation responses after chronic low-level stress and antigenic load 
(Franceschi et al., 2000). As a result, events such as cumulative amyloid plaque 
deposition and increasing concentrations of oligomeric β-amyloid with old age meet 
with an aggressive immune response (Akiyama et al., 2000, McGeer and McGeer, 
2002, Yasojima et al., 2000). 
 
Chronic innate immune system activation in the brain involving microglial activation, 
pro-inflammatory mediator release, and inflammatory cell infiltration is a feature of 
many age-related neurodegenerative disorders (Lue et al., 2010, Di Filippo et al., 
2008). In-vitro experiments have shown microglia to be induced by β-amyloid peptide, 
tau and Lewy body deposits (Tan and Seshadri, 2010, Mrak et al., 2007). Circulating 
mononuclear phagocytes also invade the brain, mediated by ligands including C-C 
chemokine ligand 2 (Ccl2) and its receptor, Ccr2 (Ransohoff et al., 2003). Aβ activation 
of microglia induces a pro-inflammatory environment in which IL-1β, IL-8, matrix 
metalloproteinases and neurotoxic products including indoleamine 2,3-dioxygenase 
are upregulated (Walker et al., 2006). Genetic variation in inflammatory pathway 
genes IL-1β, IL-1α, IL-6, and the IL-1β-converting enzyme are associated with cognitive 
function in older populations (Trompet et al., 2008, Marioni et al., 2010). 
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Immune effector glial cells are actively involved in neurotransmission and synaptic 
plasticity, including long-term potentiation - the critical process by which the brain lays 
down and retains memories (Bliss and Collingridge, 1993, Bains and Oliet, 2007, Di 
Filippo et al., 2008). Microglia also have a functional role in neuronal synaptogenesis 
and apoptosis (Bessis et al., 2007, Bezzi et al., 2001). Animal models have provided 
evidence that peripheral immune challenges compromise hippocampal synaptic 
plasticity and disrupt long-term potentiation (Chapman et al., 2010, Costello et al., 
2011). 
 
1.2.3.4 Neuropathology: vascular disease 
Cerebrovascular disease causes cognitive impairment both directly through vascular 
brain injury and indirectly through inflammation and oxidative stress (DeCarli, 2010). 
Both large- and small-vessel pathology contribute to vascular dementia (Roman et al., 
1993), and vascular pathology (including cerebral amyloid angiopathy and 
microvascular degeneration) also features heavily in AD brains. Elderly brains which 
have evidence of microvascular lesions appear to have a lower clinical threshold at 
which Alzheimer-type features and dementia become clinically apparent (Kalaria and 
Ballard, 1999, Roman, 2008).  
 
Rather than simply promoting the pathogenesis of vascular dementia, vascular risk 
factors have been suggested to increase the risk of mild cognitive impairment to AD 
(Purnell et al., 2009, Kloppenborg et al., 2008), and subsequent treatment of vascular 
risk factors appears to reduce the risk of incident AD according to one observational 
study (Li et al., 2011). 
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1.3 Biomarkers of cognitive decline  
1.3.1 The importance of biomarkers in cognitive decline 
The development of clinical features late in the progression of cognitive decline, and 
the potential benefit of altering pathological processes years before clinical features 
become apparent have fuelled the search for a biomarker of cognitive decline and the 
specific dementia subtypes. Results of this search have fuelled recent landmark 
recommendations by the National Institute on Aging and the Alzheimer’s Association 
workgroups in which they put forward a redefinition of AD (McKhann et al., 2011). 
Their redefinition moves from the assessment of purely clinical aspects of AD to the 
use of novel and putative biomarker data in confirming AD diagnosis and the 
identification of a preclinical AD stage in which currently available biomarkers identify 
neuropathological changes associated with either MCI or AD dementia before any 
clinical changes become apparent. However, despite their potential usefulness to 
these situations, current evidence presents controversy regarding biomarker tests’ 
sensitivity, specificity, availability and, particularly, invasiveness. It is important to note 
that biomarkers of AD are currently used only in research settings, not as part of 
current diagnostic procedure in the population. This is due partly to the problems 
noted above, and also as a result of their limited validation, standardisation and 
availability.   
The National Institute on Aging has published criteria for identifying biological markers 
of Alzheimer disease (Frank et al., 2003). Ideal markers should: 
 detect the fundamental CNS pathophysiology of Alzheimer disease 
 be validated in neuropathologically confirmed cases 
 be reliable, reproducible, non-invasive, simple to perform and inexpensive  
 
Ideally, biomarkers would detect disease at preclinical stages and would detect 
variation with disease progression and severity (Frank et al., 2003).  
 
The next section of this introduction presents an overview of the cognitive decline 
biomarker search, focusing on brain imaging and peripheral disease markers. The 
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overview pays particular attention to AD biomarkers, towards which most progress has 
so far been made. 
 
1.3.2 Cortical pathology imaging 
A number of imaging studies support the clinical diagnosis of dementia. Structural and 
functional magnetic resonance imaging (MRI) including volumetric measurements, and 
18F-2-deoxy-d-glucose positron emission tomography (PET) imaging of glucose 
metabolism identify regional cortical atrophy and synaptic dysfunction, particularly in 
the temporo-parietal cortex (Scahill et al., 2002). Individuals with AD often 
demonstrate non-specific MRI evidence of brain atrophy, first evident in the 
hippocampus (de Leon et al., 2006), while those with vascular dementia demonstrate 
previous vascular insult (evidence of haemorrhages and ischaemic infarcts). A major 
advance in AD imaging has been the development of novel PET ligands which bind to, 
and allow imaging of, amyloid deposition and neurofibrillary tangles (Jonghan et al., 
2008).  
 
1.3.3 Limitations of assessing cortical pathology 
1.3.3.1 Neuropathology does not always predict clinical features 
The pathological changes known to be hallmarks of dementia subtypes could present 
suitable markers for the development of each relevant subtype. However, it is 
important to note that β-amyloid plaques and Lewy bodies are both observed in 
cognitively healthy brains (Markesbery et al., 2009, Aizenstein et al., 2008) and that, 
conversely, some patients with clinical AD are found to be relatively free of neuronal 
pathology at post-mortem. (Bishop et al., 2010, Daviglus et al., 2010). Even within the 
interacting pathologies of AD, severity and number of Aβ plaques is known to correlate 
poorly with 1) neurofibrillary pathology and 2) neuronal loss. Significantly and 
surprisingly, the neuropathological changes of AD are, in fact, only moderately 
associated with functional cognitive decline (Daviglus et al., 2010). Neuropathology, 
therefore, is not a direct forecast of functional limitation in cognitive decline. 
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1.3.3.2 Cortical pathology is not an accessible disease marker in the 
population 
Pathological markers found in the brains of individuals with cognitive decline are useful 
in furthering our understanding of the disease. However, in line with NIA 
recommendations, markers of disease risk or progression need to be retrieved from a 
peripherally accessible tissue if they are to be of use in the population for screening or 
monitoring of pre-symptomatic individuals (Frank et al., 2003).  Cortical samples are 
inappropriate for use in cognitive decline risk identification or disease monitoring, 
because of their traumatic and invasive methods of procurement. Many attempts have 
therefore been made to identify a minimally invasive marker of disease progression. A 
peripheral marker which sensitively and specifically predicts risk for or change in 
cognitive decline would both aid the understanding of how to monitor, treat and 
predict cognitive decline and present a suitable marker for use in large numbers of 
pre-symptomatic individuals. 
 
1.3.3.3 Practical considerations 
Imaging studies are expensive, and availability of the instruments is a limiting factor in 
their use in preclinical, asymptomatic individuals. Despite the usefulness of imaging in 
trials and in individuals with established clinical change, these limitations mean that 
imaging does not represent an applicable measure of pathological change in the 
community. Blood, and even CSF, tests currently present more of an opportunity for 
identifying a biomarker relevant at the population level. 
 
1.3.4 Peripheral pathology 
The pathologies of cognitive decline described in section 1.2, including those 
pathologies specific to dementia sub-types, are all reflected, to a greater or lesser 
extent, in cerebro-spinal fluid (CSF) or, presenting an even more accessible tissue, in 
plasma and peripheral blood cells. Both proteomic and genomic studies have furthered 
insight into the validity of these tissues as monitors or predictors of cognitive decline. 
Recent evidence identifying significant pathological processes in the periphery, and 
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these processes’ links to functional cognitive decline, will therefore be discussed in this 
section. 
 
1.3.4.1 Peripheral markers of protein deposition  
Aβ42 and tau circulate in cerebrospinal fluid (CSF). CSF Aβ42 levels correlate inversely 
with the presence of amyloid plaques in the brain, and both CSF Aβ42 and total tau 
levels have been found to correlate with presence and development of clinical 
Alzheimer disease (Sunderland et al., 2003, Hansson et al., 2006). One research centre-
based trial (n=139) found that MCI individuals with lower CSF Aβ42 demonstrated more 
rapid cognitive impairment than those with higher Aβ42 (Snider et al., 2009). 
Furthermore, the ratio of Aβ42 to tau in the CSF has been proposed as a sensitive 
predictor of progressive memory impairment conversion from normal cognitive 
function to mild symptomatic AD (Fagan et al., 2007). This is an important finding; it 
suggests that CSF tau/Aβ42 ratio presents a pre-symptomatic risk assessment tool for 
conversion to symptomatic AD. In addition, increased CSF phosphorylated tau may be 
useful as a biomarker of neuronal injury in cognitively normal individuals (Jack et al., 
2010).  
 
In a multi-centre follow-up study assessing biomarkers, Mattsson et al. (2009) found 
significant intersite variation in Aβ42 assay use when assessing clinical Alzheimer 
disease (Mattsson et al., 2009). Variable findings from other multi-centre studies mean 
that debate remains as to the sensitivity and specificity of Aβ42 and tau testing in CSF 
for predicting or identifying AD and cognitive decline in the general population (Slats et 
al., 2010). In addition, lumbar puncture for CSF assessment is invasive and impractical 
as a screening tool. Partly due to these factors, interest has also been generated in 
protein deposition markers of dementia in blood. Soluble Aβ circulates in plasma, and 
decreasing levels of soluble plasma Aβ in cognitively healthy adults is associated with 
faster cognitive decline and may predict conversion to AD (Cosentino, 2010). However 
there is still doubt over the roles and mechanisms of soluble and oligomeric Aβ in AD 
(van Helmond et al., 2010). 
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1.3.4.2 Peripheral markers of oxidative stress 
Depleted plasma levels of antioxidants including vitamins C and E have been found to 
be associated with both MCI and AD (Rinaldi et al., 2003), indicating a potential 
systemic marker of oxidative damage in cognitive decline. A small study (n=50) 
investigating peripheral oxidative stress through DNA damage levels found higher 
oxidised DNA bases in AD and MCI groups compared to controls, and higher levels of 
DNA damage in AD and MCI patients compared to controls. The authors suggest that 
oxidative stress, demonstrated in peripheral blood cells, is a useful in vivo indicator of 
AD and of neurodegeneration (Migliore et al., 2005). 
 
1.3.4.3 Peripheral markers of inflammation 
Peripheral immunity challenges, as well as cortical stimuli, trigger neuroinflammatory 
responses in older people (Tonelli and Postolache, 2005), and studies of older 
individuals show that infection, trauma and surgery induce cognitive dysfunction that 
can persist long after physical recovery (Terrando et al., 2010, Rosczyk et al., 2008). 
The precise mechanism of this reactive cognitive decline remains unknown but all 
three causative processes trigger release of peripheral inflammatory mediators. 
Further, mouse models have shown that exposure of young mice to increased levels of 
inflammatory chemokine (C-C) motif ligand 11 (Ccl11) impairs memory, learning and 
neurogenesis (Villeda et al., 2011). Conversely, CNS inflammatory triggers are also 
known to induce peripheral inflammatory changes: peripheral leukocytes have been 
observed to infiltrate the brain in response to neuronal injury  and β-amyloid 
deposition (Babcock et al., 2003, Simard et al., 2006).  
 
Systemic inflammation has been directly associated with both AD and vascular 
dementia pathologies in humans (Holmes et al., 2009, Zuliani et al., 2007). Multiple 
proteomic and gene expression studies present evidence of inflammatory proteins in 
plasma having an association with cognitive decline. Dik et al. performed a longitudinal 
study in 1284 participants and found serum α1-antichymotrypsin (an inflammatory 
protein) to be associated with cognitive decline (Dik et al., 2005). Schram et al. 
validated this finding, though to only a moderate degree, and identified associations 
between CRP and IL-6 (two inflammatory proteins) and cognitive ability (Schram et al., 
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2007). Rafnsson et al. found IL-6 to be associated with cognitive decline in their 
prospective study of 452 individuals (Rafnsson et al., 2007). These studies all report 
small (c. 1%) but statistically significant effect sizes. Genetic investigations of 
peripheral gene expression in cognitive decline also present evidence that genetic 
variation in inflammatory pathway genes IL-1β, IL-1α, IL-6, and the IL-1β-converting 
enzyme are associated with cognitive function in large cohorts of older adults 
(Trompet et al., 2008, Marioni et al., 2010). The evidence from these large proteomic, 
transcriptomic and genetic studies suggest that peripheral inflammation may present a 
useful tool for assessing cognitive decline.   
 
1.3.4.4 Peripheral markers of vascular disease 
High levels of haemostatic markers in peripheral blood are associated with a high risk 
of atherothrombotic vascular events including small cerebral infarcts and stroke 
(Rafnsson et al., 2007), impacting on vascular dementia. In addition, individuals with a 
high atherosclerotic burden have been found to demonstrate accelerated memory 
impairment (Vinkers et al., 2005). In prospective cohort studies, levels of plasma 
fibrinogen were found to be associated (independent of major vascular comorbidity) 
with accelerated cognitive decline, and levels of D-dimers (markers of fibrin 
degradation) were also found to have a significant association with cognitive decline, 
although this finding has not been borne out by follow-up investigation (Wilson et al., 
2003, Rafnsson et al., 2007). These two markers of plasma viscosity could potentially 
indicate reduced cerebral blood flow and function as stroke predictors, or predictors of 
vascular changes in all types of dementia.  
 
1.3.5 Peripheral leukocyte gene expression may provide biomarkers 
Both hypothesis-driven and a priori case-control studies present evidence for 
peripheral blood leukocyte gene expression associations with dementia and cognitive 
impairment. Maes et al. (2007) identified leukocyte expression differences between 
matched Alzheimer disease and control individuals (total n=29) in a microarray 
experiment, Giunta et al. (2007) identified CD36 expression differences between AD, 
MCI and age-matched controls, and Grunblatt et al. (2009) identified five peripheral 
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leukocyte genes whose mRNA correlated significantly with MMSE score in 8 Alzheimer 
and control individuals (Maes et al., 2007, Giunta et al., 2007, Grunblatt et al., 2009). 
These studies made use of small cohorts of pathologically-specific dementia patients 
rather than population cohorts, but they present initial evidence that brain changes in 
cognitive decline may be echoed in peripheral leukocyte gene expression changes.  
 
The microarray study undertaken by Maes et al. (2007) used a broad coverage analysis 
of the entire genome to identify genes differentially regulated in association with 
cognitive decline, whether or not they had previously been associated with pathology. 
Their experiment demonstrated that expression changes occurred in inflammatory, 
stress response and protein processing genes, as expected from current knowledge of 
cognitive decline, but that expression changes also occurred in cytoskeletal 
maintenance and cellular trafficking genes. Their approach demonstrates that wide 
ranging expression changes are detectable in the peripheral cells of individuals with 
AD, even if the effect sizes of individual expression changes are small. 
 
1.3.6 Gene set analysis 
Furthering the evidence provided by Maes et al. that large numbers of genes in 
different functional pathways could be differently regulated in AD, two groups have 
conducted peripheral gene pathway analysis of AD: Jones et al. and Lambert et al., 
both in 2010. These studies both made use of genetic variant data from genome-wide 
association studies of large cohorts, mapping significant SNPs to genes and then 
analysing the resulting gene sets to identify groups of genes whose expression 
dysregulation is greater than expected by chance in association with AD. Both groups 
found significant overrepresentation of immune response genes dysregulated in AD 
(Jones et al., 2010, Lambert et al., 2010). Their data validate the involvement of the 
immune system in association with AD. Investigations of gene sets in association with 
cognitive decline remain to be carried out. 
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1.4 Genetic markers of cognitive decline 
1.4.1 Genetic associations with cognitive decline are limited 
Phenotypic diversity in any trait is typically due to both genetic and environmental 
influences. The complex trait of cognitive decline is significantly influenced by genetic 
variation, by epistasis and by environmental influences on gene expression (Payton, 
2009).  Heritability accounts for over 50% of the variance seen in adult cognitive 
performance (Houlihan et al., 2009) and for up to half of the inter-individual variation 
seen in age-related cognitive decline (Finkel et al., 2005). Accordingly, more than 200 
genetic studies have thus far implicated over 50 genes as having a role in cognitive 
function or cognitive decline. However, a large range of effect sizes and a paucity of 
replicated data mean that significant findings are only rarely gleaned from the 
assembled evidence (Payton, 2009). Few genes found to have an association with 
cognitive decline attain significance in the replication studies essential for their 
validation.  Initial false positive results, overestimation of effect size at initial study 
resulting in underpowered validation studies, and variance between populations may 
all contribute to this problem (Houlihan et al., 2009). Added to this complexity, 
difficulties arise in the design and analysis of studies investigating the genetic basis of 
age-related cognitive decline, with large longitudinal studies suffering selective drop-
out, attrition and practice effects. It is important to note that questions of consent and 
access to patients in longitudinal studies of changing cognitive function and reasoning 
ability affect patient participation and follow-up. 
 
Despite difficulties and a lack of unequivocal findings to date, pathways consistently 
implicated in genetic studies of cognitive decline include neurotransmission and 
metabolic pathways. In a large longitudinal study (n=1031) Houlihan et al. (2009) 
measured cognitive change from age 11 to 70. While the authors found no SNPs 
significantly associated with cognitive change, they suggested that this lack of positive 
results could be due to their application of an overly conservative Bonferroni 
correction for multiple hypothesis testing (Houlihan et al., 2009, Perneger, 1998). The 
authors therefore investigated their near-significant positive results and found that 
COMT, which codes for a dopamine degradation protein associated with prefrontal 
cognitive dysfunction (Malhotra et al., 2002), achieved near-significance in their 
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analysis. Other neurotransmitter genes (including BDNF and DRD2 (Raz et al., 2009, 
Bartres-Faz et al., 2002)) have also been associated with cognitive decline, though not 
yet validated by replication studies. Metabolic genes implicated in insulin/IGF1 
signaling and in oxidative stress response have been investigated in association with 
cognitive decline but similarly, positive results have yet to attain validation (Harris et 
al., 2007, Payton, 2009). 
 
Even with the advent of high throughput second generation sequencing techniques, 
the understanding of the relationship between genetic variation and phenotype in 
complex traits has not yet been fully understood. Payton, in his 2009 review of genetic 
research into normal cognitive ageing concludes that “given the wealth of data and 
lack of total consensus for even a single gene, we can assume that either cognitive 
genetic research has missed the large to moderate effect polymorphisms, or that small 
effect sizes and interactions will predominate” (Payton, 2009). It is hoped that 
investigation into genetic variants with synergistically small effect sizes will yield good 
insight into the mechanisms by which the heritable phenotypic variation of age-related 
cognitive decline is established (Editorial, 2010). 
 
Genetic investigation of complex traits may not provide direct biomarkers, but it 
provides key information that underlies further investigation into such traits. Strong 
evidence exists for the association between genetics and phenotype in AD, and it is the 
genetic investigation of AD that initiated current understanding and investigation of 
the disease. Accordingly, the current evidence surrounding the genetics of AD is 
presented here. 
 
1.4.2 Genes and genetics of Alzheimer disease 
While the investigation into the role of genetics in cognitive decline has met with little 
validated success, the genetics of AD, and the genes associated with both genetics and 
phenotype, have been the subject of much more fruitful discovery. 
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1.4.2.1 Early-onset Alzheimer disease 
Alzheimer disease can be inherited in an autosomal dominant fashion.  Patients with 
the inherited form of the disease comprise less than 1% of total Alzheimer disease 
cases (Ertekin-Taner, 2010), and develop symptoms of Alzheimer disease at age 40-50. 
This early-onset familial form of Alzheimer disease is determined by mutations in the 
genes coding for amyloid precursor protein, presenilin 1 and presenilin 2 (Levy-Lahad 
et al., 1995, St George-Hyslop et al., 1987, Kitaguchi et al., 1988, Sherrington et al., 
1995). The proteins are all involved in the cleavage of amyloid precursor to Aβ, and 
mutations in these genes lead to increased Aβ levels or to increased Aβ amyloidogenic 
potential (Sleegers et al., 2009). 32 mutations in APP, PSEN1 and PSEN2 have been 
linked to disease risk, and the discovery of the pivotal role of these genes in early-
onset Alzheimer disease has generated valuable insight into the pathophysiology of 
both early- and late-onset Alzheimer disease through the amyloid cascade and its 
interactions (Tanzi and Bertram, 2005).  
 
1.4.2.2 Late-onset Alzheimer disease 
The lifetime risk of late-onset AD (on which this introduction focuses) is up to twice as 
high in first-degree relatives of AD patients compared to the general population. Twin 
studies, studies of familial aggregation and transmission patterns present evidence that 
there is a substantial genetic basis for late-onset AD, which is estimated to have between 
58% and 79% heritability (Farrer et al., 1990, Van Duijn et al., 1991, Ertekin-Taner, 2010, 
McClearn et al., 1997). 
 
The most significant discovery in the field of AD genetics has been the association 
between APOE haplotype and AD (Saunders et al., 1993). Apolipoprotein E is a ligand 
in receptor-mediated lipoprotein endocytosis with three isoform variants - E2/E3/E4 – 
defined by genetic single nuclear polymorphisms (SNPs) rs429358 and rs7412 
(Cys/Arg112 and Cys/Arg158) (Su et al., 2007). APOE haplotype is the most important 
known genetic risk factor for AD, with a population attributable risk estimated at 20% 
to 70% (Ertekin-Taner, 2010). Patients who are homozygous for APOE ε4 have a 15-
fold lifetime risk of AD compared to ε3 homozygotes. Age of onset of AD also 
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decreases with ε4 hetero- and homozygosity. Notably, ε4 status is neither necessary 
nor sufficient for the development of AD (Kuusisto et al., 1997).  
 
In addition to the APOE haplotype, 14 further SNPs have been identified by genome-
wide association studies (GWAS) as having a significant association (p<1x10-8) with AD. 
These are rs2075650 in gene TOMM40, rs11136000 in CLU, rs3851179 near PICALM 
(Harold et al., 2009), rs6656401 in CR1 (Lambert et al., 2009), rs744373 near BIN1, 
rs597668 near EXOC3L2 (Seshadri et al., 2010), rs157580 in TOMM40 (Feulner et al., 
2009), rs9349407 in CD2AP, rs3865444 near CD33, rs4938933 near MS4A4A, 
rs11767557 near EPHA1 (Naj et al., 2011), rs3764650 in ABCA7,  rs610932 in MS4A6A 
(Hollingworth et al., 2011) and rs1562990 near MS4A4A (Antunez et al., 2011). Of 
these new SNPs, only the SNPs in/near CLU, PICALM, CR1 and BIN1 have been 
extensively validated. 
 
Variation at these loci is associated with risk for AD, the predominant pathological 
contributor to cognitive decline. These are genetic changes, indicating that their 
association with AD is causal rather than reactive.  What remains to be determined is 
how variation at these loci is influencing AD development and presentation, as no 
biological link between these 14 SNPs and AD has yet been established (Sleegers et al., 
2009). 
 
1.4.3 Gene expression affected by genetic variation gives insight into 
disease pathology 
The most significant of the novel SNP-AD associations (beyond APOE) described in 
1.4.2.2 has been rs11136000, an intronic SNP in CLU (chr8), identified by both Harold 
et al. and Lambert et al. at GWAS as significantly associated with AD. Based on 
rs11136000’s significance at GWAS, Guerreiro et al. (2010) genotyped the coding 
regions of CLU to further characterise its association with AD. They found no common 
coding variant associated with the disease, while 24 coding variants (including one 
nonsense mutation found in a control individual) were found in both case and control 
groups. They concluded that common coding variation fails to explain the association 
between CLU and AD, and postulated that the association may arise either from 
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altered expression of CLU as a downstream effect of cellular damage, or from genetic 
effects impacting on resting gene expression (Guerreiro et al., 2010). 
 
Over the last decade, large studies analyzing the role of genetic variability in gene 
expression control have shown that genetic variability plays not only an important role 
in coding variation but also in the regulation of gene expression abundance (Myers et 
al., 2007). This genetic regulation of gene expression contributes to phenotypic 
differences seen among individuals (Goring et al., 2007). Publically available haplotype 
maps such as the HapMap project (Consortium, 2007) allow whole-genome SNP data 
to be matched with genome-wide gene expression abundance (measured by DNA 
microarray) to generate novel data on the genetic determinants of transcript-level 
variation (West et al., 2007).  This allows variance in individuals’ genotype and 
expression abundance to be mapped, and the significant associations between the two 
identified (Mackay et al., 2009). Genetic loci at which DNA variation is significantly 
associated with gene expression traits are identified as expression quantitative trait 
loci, or eQTLs (fig. 1.2).  
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 Figure 1.2 Example of an eQTL. Taken from Gilad et al. (2008) using data from 
Stranger et al. (2007) (Stranger et al., 2007), the figure shows an example of a SNP 
acting as an eQTL for gene HLA-C. Figure (a) shows a plot of p-values (−log scale) for 
the association between individual SNPs and expression of HLA-C (y-axis) against SNPs’ 
position relative to the transcription start site (TSS) of HLA-C (x-axis). The location of 
the gene is indicated by the small red bar at the bottom of the figure. Each data point 
is for a single SNP. Figure (b) shows individual expression levels of HLA-C (y-axis), 
grouped according to the genotype of rs2249741, the most significant SNP in the 
region (indicated by the red data point in panel (a)). rs2249741, significantly associated 
with expression abundance of HLA-C, is an eQTL. 
 
Through the process of eQTL mapping, the understanding of the genomic regions 
involved in the regulation of transcription has advanced (Gilad et al., 2008) and novel 
risk loci for complex traits such as Crohn’s disease have been identified (Fransen et al., 
2010). Recently, large studies have identified thousands of putative eQTLs in the 
human genome (Gilad et al., 2008).  
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1.4.4 eQTLs 
eQTLs can act as independent regulators of gene expression, or function synergistically 
with other eQTLs (Gilad et al., 2008, West et al., 2007), exerting a regulatory effect on 
the expression of either individual genes (a cis effect, normally on a gene within 1Mb 
of the eQTL (Webster et al., 2010)) or multiple genes, commonly further abroad in the 
genome (a trans effect). Some eQTLs, known as ‘master’ eQTLs, regulate the 
expression abundance of multiple genes. eQTLs can affect expression abundance by 
influencing transcript stability, transcript structure (including the alternative splicing of 
mature mRNA transcripts), or transcription initiation (Montgomery et al., 2010). The 
location of an eQTL relative to a certain gene will give a clue as to its probable 
function; those in the 3’UTR may influence transcript stability while intronic eQTLs may 
perform a role in alternative splicing or premature transcription termination (Lalonde 
et al., 2011). 
 
An understanding of the functional role of eQTLs brings the study of complex traits 
closer to understanding the significant and causative links between genome, 
transcriptome and phenotype. 
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1.5 Aims and objectives 
This project aimed to identify significant associations between cognitive performance, 
cognitive decline and peripheral leukocyte gene expression, in line with recent 
evidence supporting such associations. The project made use of evidence from recent 
genetic work and from a transcriptome-wide expression analysis in a cognitively 
characterised cohort to achieve this aim. The population-based InCHIANTI cohort 
provided peripheral blood samples, and global gene expression analysis was conducted 
using these samples.  
 
The two phases of the study were: 
1. genome-wide expression analysis to identify peripherally expressed genes 
associated with cognitive performance or cognitive decline 
2. candidate-driven investigation of SNPs associated with cognitive decline as 
potential modulators of gene expression abundance and phenotype 
 
First, the study investigated the association between peripheral blood leukocyte gene 
expression, cognitive function and cognitive decline in a global gene expression study. 
This provided the first large-scale population data on the significance of peripheral 
immune cell expression in cognitive impairment and cognitive decline. This study 
phase analysed both individual gene expression associations with cognitive decline, 
and the associations between cognitive decline and gene pathways, to investigate 
whether groups of related genes e.g. peripheral inflammatory or immune pathways 
had significant associations with cognitive decline. 
 
Second, this study made use of published genetic variant associations with AD to 
investigate whether these variants were impacting on the disease by altering gene 
expression abundance. This eQTL analysis aimed to further the understanding of the 
functional link between genetics, gene expression and clinical change in cognitive 
decline. 
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Study objectives were therefore to: 
1. Identify cognitively characterized study participants with good quality global 
gene expression data to create a functionally significant phenotype of cognitive 
performance and cognitive decline in eligible participants 
2. Use global gene expression microarray data to analyse individual gene 
expression associations and gene pathway associations with cognitive 
performance/decline in these participants 
3. Perform an eQTL analysis of AD- or cognitive decline-related SNPs and analyse 
association of any eQTL-targeted genes with cognitive performance and 
cognitive decline 
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Chapter 2 Methods 
2.1 Cohort 
2.1.1 InCHIANTI study 
This study made use of cohort data from the Invecchiare (Ageing) in Chianti study 
(InCHIANTI) (Ferrucci et al., 2000). The InCHIANTI study is a prospective population-
based epidemiological study of ageing whose participants come from two towns in 
Chianti (Tuscany), Italy. The InCHIANTI study is headed by principal investigator Dr. 
Luigi Ferrucci at the Gerontology Research Centre at the National Institute on Aging, 
Baltimore. 
 
The study was initiated in 1998 with the aims of furthering the understanding of the 
risk factors contributing to difficulties in later life, and promoting standardised criteria 
that would help establish the normal ranges of function in older people across 6 
specific physiological subsystems: the central nervous system, perceptual system, 
peripheral nervous system, muscles, bone/joints, and energy production/delivery. 
Over 1400 participants enrolled. To date, participants have undergone extensive 
interview and examination every 3 years since enrollment. Peripheral blood samples 
were taken from over 700 participants at their 4th interview, 9 years after enrollment. 
 
Data from the InCHIANTI cohort has previously been used to investigate cognitive 
decline and cognitive impairment in association with socio-economic status 
(Marengoni et al., 2011), serum vitamin D levels (Llewellyn et al., 2010), and thyroid 
dysfunction (Ceresini et al., 2009). 
 
2.1.2 Sample description 
The 1453 InCHIANTI participants in the study came from two areas in Tuscany:  Bagno 
a Ripoli, an urban area on the border of Florence (4704 inhabitants, 20.3% aged 65 or 
over), and Greve in Chianti, a neighboring rural area (11,709 inhabitants, 19.3% aged 
65 or over). The study population consisted principally of individuals aged ≥65 years at 
enrollment. 
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Population registries for the two areas were used by collaborators in Tuscany to 
randomly select 1270 individuals aged ≥65 in August 1998. 29 additional individuals 
aged ≥90 years were also randomly selected to participate until 30 men and 30 women 
from this age group had been selected. Of these 1299 individuals selected from 
registries, 17 men and 22 women were ineligible for the study because they had either 
died or left the area. Individuals from younger age strata (20-29, 30-39, 40-49 and 50-
59) were also randomly selected and invited to participate until 30 men and 30 women 
from each decade were enrolled in the study. 10 men and 10 women from the 60-64 
age group were also enrolled. Of the 1616 individuals initially selected for inclusion, 
1453 agreed to participate in the study: participation rates were 91.6% among those 
≥65 years and 69.4% among those <65 years. Summary statistics for the InCHIANTI 
individuals eligible for the current study are given in section 2.6.1.3. 
 
2.1.3 Interviews 
Contact with patients consisted of a detailed interview in participants’ homes followed 
by a thorough clinical assessment by a doctor in a study clinic. This assessment took 
place at years 0, 3, 6 and 9 of the study, providing (to date) 4 waves of interview and 
clinical data. At interview, participants answered questions relating to their perceived 
current health, functional status and ability to perform activities of daily living (ADLs), 
as well as questions about their diet, smoking habits, social networks, taught education 
and economic status. They also undertook a Mini-Mental State Examination. For those 
patients who were unable to respond to questions due to hearing or aphasic problems, 
interviews were administered through a proxy. 
 
A total of 1140 individuals ≥65 years old (492 men and 648 women) and 296 
individuals <65 years old (142 men and 154 women) completed their first interview. 
Subsequently, 1089 participants attended for interview and examination at year 3, 942 
attended at year 6, and 733 attended at year 9 (from 900 surviving participants). 
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2.2 Ethical approval 
Ethical approval for the InCHIANTI study was granted by the Instituto Nazionale Riposo 
e Cura Anziani institutional review board in Italy. All study participants gave written 
informed consent to participate and for the collection of samples after having received 
an extensive description of the procedures, purposes and potential risks of the study.  
For those persons who could not fully consent because of physical or cognitive 
impairments, proxy consent from a close relative was obtained. Ethical approval for 
subject genotyping was approved by the Italian National Institute of Research and Care 
of Aging Institutional Review board.  
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2.3 Mini-Mental State Examination 
The MMSE tests 11 cognitive domains: orientation, registration, attention, calculation, 
recall, naming, repetition, comprehension (verbal and written), writing and 
construction. A low score indicates cognitive impairment, and a cut-off between 22 
and 27 points is used in different settings to distinguish normal cognitive functioning 
from cognitive impairment (Mitchell, 2009). Scores are dependent on subjects’ age, 
sex and educational level (Grigoletto et al., 1999). In the InCHIANTI cohort, an MMSE 
score of 24 or less has been identified as a sensitive cut-off for cognitive impairment 
(Geroldi et al., 2005). 
 
2.3.1 MMSE assessment 
Participants’ cognitive ability was assessed at each interview wave using the MMSE 
(scored out of 30 points). Interviews and examination conducted at each wave of 
assessment allowed the trajectory of participants’ cognitive decline to be mapped over 
the 9 years of their follow-up. 
 
Participants were considered eligible for this study if MMSE scores were recorded at 
both year 0 (baseline) and year 9 of follow-up (n=691). MMSE score change over time 
was used as the measure of cognitive decline over 9 years. For further participant 
selection in the eQTL phase of this study, cognitive impairment was defined as a MMSE 
score of 24 or less.   
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2.4 Blood collection 
Blood sample collection and storage was performed by collaborators in Tuscany. At the 
9-year follow up examination in 2008/9, 2.5ml peripheral whole blood samples were 
collected from all attending participants (n=733) directly into PAXgene Blood RNA 
Tubes (Qiagen, Crawley, UK) according to the manufacturer’s instructions and stored 
at -80oC. Cell-stabilising PAXgene reagents (a mixture of cationic detergent and salts) in 
these tubes protected RNA from ribonuclease (RNase) degradation and minimised the 
effects of ex vivo factors such as temperature changes, handling time and shipping 
conditions on peripheral blood mononuclear cell RNA yield, integrity and purity. This 
preserved the intracellular RNA profile as it was in-vivo at the point of extraction. 
 
The use of the PAXgene blood RNA system is well documented as a reliable method for 
optimising RNA quality prior to large-scale gene expression profiling (Debey-Pascher et 
al., 2009). Early studies raised queries as to the PAXgene stabilisation system’s ability 
to maintain transcript stability (Kagedal et al., 2005), but subsequent studies have 
shown RNA yield, integrity and purity to remain high in samples extracted using the 
PAXgene system and stored at -80oC for 6 months (Weber et al., 2010). Cellular RNA 
can be stabilised in PAXgene Blood RNA tubes for at least 50 months at -20oC or -70oC 
without any alterations in RNA levels (data from manufacturers) (www.qiagen.com, 
2010). 
 
PAXgene blood RNA technology has been shown to be suitable for use with the 
Illumina genome-wide expression assays which form a key part of this investigation 
(Debey-Pascher et al., 2009). 
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2.5 Expression profiling 
2.5.1 RNA extraction and purification 
RNA isolation, purification and quality control steps were performed by Dr. Murray’s 
lab at PCMD within 6 months of blood collection using the PAXgene blood RNA kit 
(Qiagen, Crawley, UK) according to the manufacturer’s instructions. Automated RNA 
purification was carried out on the QIAcube workstation (Qiagen, Crawley, UK) using 
the PAXgene blood RNA protocol according to the manufacturers’ instructions. The 
automated procedure comprised nucleic acid pellet buffering, cell lysate 
homogenisation, and centrifugation of fractionated supernatant through a silica 
membrane to selectively bind RNA. RNA was washed, added to elution buffer and the 
solution denatured at 65oC. Purified RNA samples were aliquotted, immediately placed 
on ice and frozen at -80oC to prevent RNA degradation. At this temperature, RNA is 
expected to remain stable for 2 years (Vartanian et al., 2009). Samples were stored in 2 
x 40μl aliquots of elution buffer to reduce freeze-thaw cycling.  
 
For this study, RNA was isolated from whole blood. Although leukocyte isolation 
protocols can result in a better signal-to-noise ratio and greater sensitivity for total 
RNA isolation than whole blood RNA isolation, these were not conducted for two main 
reasons. Firstly, the cell fractionation necessary for these additional leukocyte isolation 
steps can invoke gene expression artefacts (Vartanian et al., 2009). Secondly, when 
considering large-scale expression studies, the additional protocol steps necessary for 
leukocyte isolation make RNA isolation slower and less cost-effective than rapid RNA 
isolation from whole blood. 
 
2.5.1.1 Quality control 
Dr. Murray’s group performed RNA quality control (QC) steps. RNA yield and 
concentration were determined by UV absorbance at 260nm and 280nm using a 
NanoDrop 1000A spectrophotometer (NanoDrop, Wilmington, USA) for which A260=1 
equates to a yield of 44μg RNA/mL.  RNA purity was quantified by the ratio of 
absorbance at 260nm (nucleic acid UV absorbance) and 280nm (protein UV 
absorbance). Samples were deemed of sufficient purity if the A260/A280 ratio >1.8.  In 
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addition to spectrophotometry, 10 RNA samples were selected randomly to undergo 
separation by agarose gel electrophoresis. This demonstrated good quality RNA with 
strong 18S and 28S bands and limited RNA degradation.  Total RNA that passed 
concentration and purity QC steps (n=722) were eligible for RNA amplification and 
microarray expression quantification. 
 
2.5.2 Reverse transcription and amplification 
Before application to the expression microarray, RNA was reverse transcribed and 
amplified. This was performed in 14 batches by Prof. Singleton’s lab in Washington 
using the Ambion TotalPrepTM RNA Amplification Kit for Illumina arrays (Applied 
Biosystems, California, USA) according to standard microarray analysis protocol. The 
Ambion TotalPrepTM Kit can amplify RNA across the range 50-500ng.  
 
Using the Ambion RNA amplification kit, RNA was reverse transcribed with oligo-dT 
primer and a 5’ RNA polymerase promoter. Complementary DNA (cDNA) synthesis 
with DNA polymerase and RNA degradation with RNAse were followed by purification 
to remove primers, enzymes and salts, resulting in the formation of purified second 
strand cDNA. Multiple copies of antisense biotin-labelled cDNA were transcribed using 
DNA polymerase alongside excess nucleotides and biotin-labelled uridine triphosphate 
(UTP). Labelled cDNA was re-purified to remove unused nucleoside triphosphates 
(NTPs), enzymes, salts and inorganic phosphate. Purified, amplified and biotinylated 
cDNA was then applied to the expression microarray. 
 
2.5.3 BeadChip hybridisation 
Expression profiling for the whole transcriptome of each participant was conducted by 
the Singleton lab using RNA directly hybridised to Illumina HumanHT-12 v3 Expression 
BeadChips (Illumina, San Diego, USA). BeadChip profiling was conducted in 10 
hybridisation batches run consecutively.  
 
HumanHT-12 v3 BeadChips include 48,803 probes containing 50-base oligonucleotide 
probe sequences designed using the National Centre for Biotechnology Information 
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Reference Sequence collection (RefSeq) to hybridise to specific transcript targets in the 
polyA tail of RefSeq and UniGene annotated genes, and in putative genes and splice 
variants, to allow whole-genome gene expression profiling. Each probe has an 
associated unique 29-base address sequence at its 3’ end, allowing probe identification 
and decoding during microarray scanning. Per chip, each probe sequence is bound to 
approximately 30 different silica beads; this allows for high data reproducibility.  
 
The Human_HT-12 v3 Expression BeadChip requires an input of 50-500ng RNA. 
Biotinylated cDNA samples were added to their BeadChips with proprietary buffers, 
then incubated at 65oC for 30 minutes and overnight at 58oC to allow hybridisation to 
complementary probes to take place. After hybridisation, microarrays were washed, 
and Cy3-streptavidin added. Cy3-streptavidin fluoresces at 570nm when bound to 
biotin, allowing relative abundance of each cDNA transcript to be calculated from 
image data captured by Illumina iScan hardware (Illumina, San Diego, USA). Illumina 
BeadStudio software was used for data visualisation, analysis (including microarray 
decoding) and quality control. Normalised hybridisation intensities were taken to 
represent probe expression abundance. 
 
2.5.3.1 Quality control 
Microarray quality control was performed by Prof. Singleton’s group in Washington. All 
microarray experiments and analyses complied with MIAME (Minimum Information 
About a Microarray Experiment) guidelines, meeting the minimum information 
required to unambiguously interpret microarray data. 
 
Hybridisation intensities were normalised using the mean and standard deviation of 
baseline intensity of each probe over all beads, using the BeadStudio cubic spline 
normalisation algorithm. Quality control steps involved quantile normalisation across 
arrays, calculation of detection p-values using negative control probes, correction of 
baseline intensities for local background effects by background subtraction and 
normalisation, calibration to expression intensities of abundantly expressed 
endogenous housekeeping genes, and calculation of 5th and 95th intensity percentiles 
for removal of outlier beads or arrays. Transcripts detected in less than 5% of samples 
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were excluded from analysis. Samples in which all expression intensities were ±3 
standard deviations from the mean were excluded, and samples for which the 
proportion of expressed probes was less than 3 standard deviations from the mean 
were also removed from analysis. 16,571 of the original 47,000 probes passed QC 
exclusion steps. All QC-passed probe expression intensities were transformed to a base 
2 logarithmic scale prior to expression statistical analysis. This was done to normalise 
expression data, which often varies by orders of magnitude. 
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2.6 Global gene expression analysis 
2.6.1 Sample and probe selection 
2.6.1.1 Cognitive performance analysis 
All 691 individuals with MMSE performance recorded at the time of blood draw for 
whom QC-passed microarray expression data was held were eligible for association 
analysis between genome-wide gene expression and cognitive performance at time of 
blood draw. All QC-passed microarray probes were eligible for analysis (n= 16,571). 
Results section 3.2 describes these eligible samples and probes in further detail.  
 
2.6.1.2 Cognitive decline analysis 
For all individuals whose MMSE score was recorded at time of blood draw, MMSE 
score had also been recorded at baseline. 691 individuals were therefore eligible for 
analysis of MMSE performance decline over 9 years. Individuals were not excluded on 
the basis of any additional medical, medication or lifestyle information as existing 
studies present either no evidence or inconclusive evidence for any influence for these 
factors on cognitive decline. All 16,571 QC-passed microarray probes were eligible for 
analysis.  
 
2.6.1.3 Summary participant statistics  
Table 2.1 gives the summary statistics for the 691 eligible participants for whom 
sufficient cognitive data was held and whose RNA and microarray samples passed all 
QC steps 
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Table 2.1 Summary participant statistics. A summary of the 691 eligible individuals’ 
age, sex, MMSE score at enrollment and at blood draw (9 years later), site of 
enrollment, educational attainment and lifetime pack-years of smoking (1 pack-year 
equivalent to  20 cigarettes smoked per day for 1 year) is given in the table  
 
Summary statistics 
Age N 
30-49 86 (12.5%) 
50-69 98 (14.2%) 
70-89 479 (69.3%) 
90-104 28 (4%) 
Mean age at RNA collection 72.6 (SD: 15.3) 
 
Gender % 
Men 44.8 
Women 55.2 
 
MMSE  
Mean score at blood draw 25.58 (SD: 5.66) 
Mean score 9 years previously 26.89 (SD: 2.57) 
 
Site % 
Greve 48.91 
Bagno a Ripoli 51.09 
 
Education % 
Nothing 13.31 
Elementary 46.02 
Secondary 13.46 
High school 12.59 
University / Professional 14.62 
 
Pack-years smoked (lifetime) % 
None 55.72 
0.1-20 22.87 
20-39 14.33 
40+ 7.09 
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2.6.2 Statistical analysis 
2.6.2.1 Cognitive performance 
All statistical analyses were performed using Stata v10 software, except where stated.  
 
Associations between log-transformed probe expression intensities and MMSE score 
at blood draw were analysed in a multiple linear regression model. All phenotype-
expression association analyses were adjusted for potential microarray amplification 
and hybridisation batch effects (as categorical variables, 14 and 10 categories 
respectively), and for participants’ study site (categorical as either a rural setting, 
Greve in Chianti, or an urban setting, Bagno a Ripoli), age (as a continuous trait), sex 
(categorical), lifetime pack-years smoked (in five categories: none, less than 20 years, 
20 to 39 years, 40 plus years, and missing), highest level of education received (in five 
categories: none, elementary, secondary, high school, and university/professional), 
and percentage of different types of leukocyte present in each blood sample (as a 
continuous trait for 4 types of leukocyte: lymphocytes, neutrophils, monocytes and 
eosinophils). Recent evidence suggests a reduction in circulating B-cell populations in 
individuals with AD (Pellicano et al., 2010). Associations were taken to be statistically 
significant if they achieved a nominal p-value <0.05 and a q-value <0.1 (see section 
2.6.2.3 for more on the use of q-values). A q-value cut-off of 0.25 is typical for false 
detection rate analyses, representing a 25% chance that the nominal p-value shows no 
deviation from chance. The chosen cut-off q-value of 0.1 represents a more stringent 
10% probability that the p-value is due to chance. 
 
2.6.2.2 Cognitive decline 
Associations between probe expression intensities and cognitive decline over 9 years 
were tested using a multiple linear regression model with log-transformed gene 
expression level as the independent variable and MMSE change between baseline and 
blood draw as the continuous dependent variable. The potential confounding factors 
taken into account in the regression model were, as in the cognitive performance 
model detailed in section 2.6.2.1, potential microarray amplification and hybridisation 
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batch effects, participants’ study site, leukocyte type percentages, age, sex, lifetime 
pack-years smoked and educational attainment. 
 
2.6.2.3 Adjustment for multiple hypothesis testing 
All 16,571 QC-passed probes were tested simultaneously for their individual 
associations with cognitive performance, and then again for associations with cognitive 
decline. Testing this volume of associations concurrently with a nominally acceptable 
p-value of 0.05 would result in an expected 800 false positive results. These hypothesis 
tests were therefore also subjected to multiple testing corrections. 
 
The most common method for adjusting results of multiple hypothesis tests to 
improve determination of significant results is the Bonferroni adjustment. The 
Bonferroni adjustment lowers the p-value threshold necessary for declaring 
significance according to the number of tests performed, reducing the number of false 
positive results generated but also significantly reducing the number of true positive 
results identified. The adjustment is therefore overly conservative as a multiple testing 
correction (Perneger, 1998). This study used a different principle to limit the number 
of false-positives yielded by such a large investigation: the False Discovery Rate-
adjusted p-value (termed the q-value). This approach was less conservative than the 
Bonferroni adjustment and had greater power to identify true positive results in tests 
of multiple hypotheses (Storey and Tibshirani, 2003).  
 
By chance, multiple hypothesis tests produce p-values across the entire range 0-1. Q-
value calculation uses the p-value distribution generated by a set of hypothesis tests to 
take into account the likely distribution of “chance” p-values across this range. A q-
value is generated for each nominal p-value based on the proportion of true positive p-
values to false positives likely for each given p-value, given the assumed “chance” p-
value distribution. Low p-values are only deemed significant if the frequency of 
similarly low p-values is enough to suggest that the p-values are not the results of 
chance alone i.e. if the ratio of true positives to false positives is high. A nominated q-
value cut-off determines what percentage of false positives would be acceptable for 
each nominal p-value to declare statistical significance.  
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In summary, an association would need both a low p-value (indicating a nominally 
significant association) and a low q-value (indicating that the proportion of false 
positives for this given p-value is likely to be low) to be deemed significant after a 
multiple hypothesis test. 
 
In these analyses, expression levels were taken to have a significant association with 
cognitive decline if their association achieved a nominal p-value <0.05 and a q-value 
<0.1. 
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2.7 Inflammatory subset analysis 
2.7.1 Selection of probes for analysis 
For inflammatory subset analysis, inflammatory gene probes were identified by Luke 
Pilling at PCMD. The Broad Institute’s Molecular Signatures Database (MSigDb) was 
used to select inflammatory/immune genes as defined by the Gene Ontology project. 
An MSigDb search for “inflamm* OR immune* OR cytokine*” identified both the gene 
sets relevant to this analysis and individual genes’ associated expression probes. 
Constituent probes which were included on the Illumina Human_HT12 v3 microarray 
and which passed microarray QC steps across the InCHIANTI samples (n=1228) were 
eligible for analysis of association with cognitive performance and cognitive decline. 
 
2.7.2 Statistical analysis 
As described in section 2.6.2.1, associations between logged probe expression 
intensities and cognitive performance/decline over 9 years were tested using a linear 
regression model with log-transformed gene expression level as the independent 
variable and either MMSE performance at blood draw or MMSE change between 
baseline and blood draw as the continuous dependent variables. The potential 
confounding factors taken into account in the regression models were microarray 
amplification and hybridisation batch effects, participants’ study site, leukocyte type 
percentages, age, sex, lifetime pack-years smoked and educational attainment.
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2.8 Gene pathway analysis 
2.8.1 Probe data collapse to relevant genes 
The Illumina Human_HT-12 microarray contains probes that tag different isoforms of 
the same gene. For those genes targeted by multiple probes, gene symbols and the 
probe mappings to each gene given in the Illumina annotation file were used by Luke 
Pilling at PCMD to collapse probe expression data into representative gene expression 
data (regardless of isoform) by taking the median intensity of probes representing 
each gene to represent that gene’s expression intensity. Probes with no known 
mapping to a gene symbol were left unchanged in the data set. 
 
2.8.2 Selection of pathways for analysis 
Molecular or biological function pathways were identified with Luke Pilling at PCMD 
using Gene Ontology gene sets from the molecular signature database (MSigDB) 
(http://www.broadinstitute.org/gsea/msigdb/index.jsp) (Subramanian et al., 2005). 
MSigDB catalogues gene sets by 5 different categories. For this project, the gene 
ontology collection category was used to identify relevant gene sets.  
 
The gene ontology database was initiated in 2000 to promote consistent description of 
gene products across different databases (Ashburner et al., 2000). Gene ontology 
provides a controlled vocabulary by which to define gene functions and processes, 
allowing genes to be organised and grouped into their relevant sets. These sets 
comprise biological processes, molecular functions and cellular components. Genes 
can function in a number of ontology processes or groups. There are 1454 gene sets 
named by gene ontology terms (825 biological processes, 396 molecular functions and 
233 cellular components), all of which were considered for eligibility in this analysis. 
 
Before analysis, gene sets containing less than 15 or more than 500 genes were 
excluded to avoid testing overly narrow or broad functional categories, according to 
the method of Wang et al. (2007) (Wang et al., 2007). 
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2.8.3 Gene set enrichment analysis (GSEA)  
GSEA software from the Broad Institute (www.broadinstitute.org/gsea) was used to 
analyse the association between gene sets and cognitive performance or cognitive 
decline  by analysing the association of all genes within each set concurrently with the 
continuous phenotypes as previously described (Subramanian et al., 2005). GSEA uses 
a ‘no cut-off’ strategy that assesses the association of every gene with phenotype, 
rather than simply considering those genes which have a statistically significant 
association with phenotype or a large effect size. 
 
The GSEA algorithm used inputted expression data and phenotype data to rank genes 
according to the magnitude of their association with the continuous variables of 
cognitive performance (MMSE performance at blood draw) or cognitive decline 
(change in MMSE performance over 9 years between baseline and blood draw). Genes 
with the strongest positive association with phenotype were highly ranked, and genes 
with the strongest negative association with phenotype held low ranks. The algorithm 
walked down the ranked list of genes once for each considered gene set. As it did so, 
the algorithm increased a gene set’s “enrichment score” when it encountered a gene 
in the selected pathway and decreased the score when an encountered gene was not 
in the chosen pathway. Genes encountered at the extreme ends of the rank list 
increased score by greater magnitude than middle-ranking genes. By this method, a 
maximum enrichment score was generated for each gene set. 
 
Gene sets or pathways containing genes clustered towards the strongly positively 
associated rankings were considered positively associated with phenotype, while sets 
containing genes clustered towards the strongly negatively associated rankings were 
considered negatively associated with phenotype. 
 
2.8.4 Residual expression input into algorithm 
Different to a regression model, the GSEA algorithm does not allow analysis to be 
adjusted for potentially confounding factors. For this reason probe expression values 
were adjusted before input into the algorithm. This was performed by Luke Pilling at 
PCMD using residual analysis of each probe’s regression model (using Stata v10 
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software). Removal of the variance in probe expression accounted for by each 
potentially confounding factor (as used in the regression models detailed in section 
2.6.2) left probes’ residual variance ready to be inputted into the algorithm. This 
minimised the potential effects of confounding factors on GSEA association analyses. 
 
2.8.5 Statistical analysis 
For each gene set, a maximum enrichment score (ES) was calculated by the algorithm 
from the rank order of every gene in the gene set using a weighted enrichment 
statistic. This ES was then compared to 1000 randomly sorted ES distributions to 
produce an enrichment score p-value using a Kolmogorov-Smirnov-like statistic. Gene 
sets that had a statistically significant (nominal p-value<0.01, q-value<0.25) 
overrepresentation at the top or bottom of the ranked association list were taken to 
be significantly associated with cognitive decline as previously described (Subramanian 
et al., 2005).  
 
The weighted enrichment statistic used to calculate ES for each gene set was scaled as 
a function of gene set size. All enrichment scores were therefore normalised for gene 
set size.  
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2.9 eQTL analysis  
2.9.1 Genotyping 
Genome-wide genotyping was performed by Prof. Frayling’s group at PCMD using 
750ng of genomic DNA from whole blood samples extracted in 9ml EDTA tubes after 
overnight fasting. Genotyping of autosomal SNPs was performed on Illumina Infinium 
HumanHap550 genotyping BeadChips (ver1 and ver3 used) (Illumina, San Diego, USA), 
using the Infinium Assay (Illumina) according to the manufacturer’s instructions. Both 
alleles of each SNP were assayed. 
 
Tag SNPs (acting as proxies for multiple common SNPs) were identified from phases I 
and II of the International Haplotype Map Project (www.HapMap.org) and chosen for 
their high linkage disequilibrium statistic (r2) with other autosomal SNPs. 90% of 
HapMap loci with a MAF ≥0.05 are covered by at least one tag SNP on the Illumina 
BeadChip. 
 
Whole genome DNA was amplified and fragmented; resuspended fragments were then 
added to Illumina BeadChips and incubated to allow locus-specific hybridisation. 
Hybridised DNA was fluorescently stained and ddNTP fluorescence intensity measured 
using Illumina BeadStation scanners (Illumina, San Diego, USA). Fluorescence intensity 
was used to quantify the relative intensity strength at each locus for both alleles to 
identify individuals’ genotype at each SNP. Data analysis was performed in Illumina 
BeadStudio v3 (Illumina, San Diego, USA). Genotype calls (identification of SNP probes 
passing detection filter score) were made using the standard cluster files provided by 
Illumina. Imputation of genotypes not captured by the HumanHap550 chips was 
performed using MaCH v1.0.16 haplotyper software 
(http://www.sph.umich.edu/csg/abecasis/MACH/index.html) and haplotype reference 
panels from HapMap r22 and June 2010 release of the 1000 Genomes project 
(Consortium, 2007, Consortium, 2010). 
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2.9.1.1 Quality control 
Genotyping QC was performed for 1231 InCHIANTI samples by Prof. Frayling’s group at 
PCMD. Samples with a genotype success rate below 98% (n=87) were repurified and 
regenotyped: following this step, 48 samples were successfully genotyped and re-
eligible for analysis. Samples with non-concordant gender as reported by genotype and 
interview (n=9) were excluded. 48 samples were therefore excluded at this stage; 1183 
remained eligible for SNP quality control steps. SNP QC steps were performed using 
Illumina BeadStudio software. Outlier SNPs were removed if their allelic intensities 
were <1st intensity percentile or >99th percentile. Uniform sampling of 400 points along 
each intensity axis allowed background, rotational and sheer estimation to provide 
normalised intensities for each chip.  
 
Illumina BeadStudio software was also used to perform genotype calling. SNPs were 
excluded from analysis if they were called in <98% of samples or had a minor allele 
frequency of <1%. SNPs which deviated significantly (p<1x10-4) from the expected 
population distribution as calculated by the Hardy-Weinberg equilibrium were also 
excluded. Imputed SNPs (n=6,858,242) were excluded if their minor allele frequency 
<1% and if their r2 with called SNPs <0.3 or <0.5, depending if they were based on the 
HapMap or 1000 Genomes panels respectively (Wood et al., 2011). After QC steps, 
496,032 genotyped SNPs were available for analysis. 
 
 
2.9.2 SNPs chosen for eQTL analysis 
To date, no SNPs have been identified as significant for cognitive decline or vascular 
dementia in genome-wide association studies. Published genome-wide association 
studies for AD were collated, and SNPs with a significant association with AD (p≤1x10-8) 
were identified from these publications. These SNPs significantly associated with AD 
were selected for gene expression association analysis to identify significant eQTLs. 
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2.9.3 Proxy search 
Perfect linkage disequilibrium (see section 2.9.4) of a suspected eQTL with an 
additional SNP could mean that the identified eQTL is perfectly marking a functional 
variant rather than acting as the functional variant.  
 
The publicly available SNAP server (www.broad.mit.edu/mpg/snap) was used to 
identify further local SNPs (within 500kb of significant SNPs) in perfect linkage 
disequilibrium with significant SNPs as assessed by their r2 values. The SNAP server 
uses Haploview 4.0 software (Barratt et al., 2005) to combine genotyping, genetic 
mapping and recombination data from the International HapMap Project and the 1000 
Genomes Project. SNAP uses this data to compute pairwise linkage disequilibrium 
statistics between local SNPs (often genotyped by different genotyping arrays) to allow 
identification of SNP proxies (Johnson et al., 2008). 
 
 
2.9.4 Linkage disequilibrium 
r2 is a derived measure of linkage disequilibrium, the non-random association of alleles 
at 2  genetic loci. If one locus has alleles A and a, and another locus has alleles B and b, 
r2 is the squared correlation between alleles A and B, given by the formula  
r2 =  D2AB/(PA x Pa x PB x Pb)  
where D is the difference between the observed frequency of haplotype AB and the 
frequency that would be expected if the two alleles were segregating randomly, PA = 
frequency of allele A at locus 1 and PB = frequency of allele B at locus 2. D is calculated 
as the observed frequency of haplotype AB – the expected frequency of haplotype AB, 
calculated by frequency of allele A x frequency of allele B, or  
DAB = PAB-(PA x PB). 
 
Repeated recombination and recurrent mutation lessen the association between two 
loci, decreasing the observed frequency of haplotype AB, and therefore decreasing the 
disequilibrium (D) between allele A and allele B. As a measure of this disequilibrium, r2 
has the range 0 to 1. r2=1 occurs when the allele at locus 1 always exactly predicts the 
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allele at locus 2. If r2=1, the two SNPs function as proxies for each other, and are 
always observed together. 
 
2.9.4 Genes chosen for eQTL analysis 
eQTLs can exert an effect on either single genes or over many genes  through affecting 
both local promoter and splicing effects and by distant transcription factor and RNA 
stability regulation (Dixon et al., 2007, Veyrieras et al., 2008) (see section 7.7.3 for 
more on cis- and trans-eQTLs). The aim of this study phase was to investigate the 
function of SNPs a priori, with no assumptions made about the genes affected by their 
activity. Analysis therefore first involved a local search for genes whose expression had 
a significant association with genotype to identify putatively cis-eQTLs, and then a 
genome-wide search to validate significant eQTLs and identify possible trans-acting 
eQTLs. 
 
For the initial (local) gene search, genes whose transcription start site lay within 500kb 
of any AD-associated SNP were considered for their association with genotype at 
putative cis-acting eQTLs; global eQTL studies have found the majority of cis-eQTLs to 
lie within this range of target genes’ transcription start sites (Bennett et al., 2010, 
Veyrieras et al., 2008). The University of Santa Cruz Genome Browser 
(http://genome.ucsc.edu/cgi-bin/hgGateway) was used to identify unique genes in 
500kb proximity of any of the 14 SNPs. Local genes for which at least one QC-passed 
expression probe’s data was held in the InCHIANTI population were eligible for 
genotype-expression analysis. 
 
2.9.5 Genotype-expression analysis 
Associations between genotype at eligible SNPs and logged expression intensities of 
eligible local probes were analysed in every InCHIANTI participant for whom QC-passed 
microarray data and SNP genotypes were available (n=613). Statistical significance of 
associations was assessed using a multiple linear regression model adjusted for 
participants’ age, sex, lifetime pack-years smoked and highest level of education 
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received, as well as for site of RNA extraction, percentages of different leukocyte types 
present in whole blood, and potential amplification and hybridisation effects. 
 
Genotype-expression associations were considered significant if they achieved a 
nominal p-value<0.001 and a q-value<0.001. This stringent cut-off was used in line 
with previous groups’ publications on eQTL identification (De Jager et al., 2009). SNPs 
significantly associated with gene expression were considered expression quantitative 
trait loci (eQTLs) in this cohort. 
   
2.9.6 Expression-phenotype analysis 
Genes whose expression had a significant association with eQTL genotype were chosen 
for quantitative real time reverse transcription-polymerase chain reaction (qRT-PCR) to 
allow sensitive analysis of the association between their expression and the derived 
phenotype of cognitive decline. Before the publication of AD GWAS findings by Naj et 
al. and Hollingworth et al. in April 2011, and then Antunez et al. in May 2011, only two 
genes (BIN1 and PVRL2) were known to have a significant association with a AD-
associated eQTL. These two genes were therefore chosen for expression-phenotype 
analysis. 
 
The validity and reliability of microarray expression analysis is becoming comparable 
with qRT-PCR, but qRT-PCR remains the gold standard of RNA expression 
quantification and validation, having the advantages of superior detection and 
quantitation, and a lower frequency of quantification error than whole-genome 
profiling (VanGuilder et al., 2008, Blalock et al., 2005). Gene expression abundance 
was therefore quantified using two-step qRT-PCR using the SuperScript® VILO™ cDNA 
synthesis kit (Invitrogen, Paisley, UK) for reverse transcription and TaqMan Low 
Density Arrays (Applied Biosystems, California, USA) for the quantitative real-time 
polymerase chain reaction. 
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2.9.7 Selection of eligible participants 
722 QC-passed RNA samples were held for InCHIANTI individuals. qRT-PCR using the 
TLDA system (see section 2.9.9) requires 1μl of RNA from each sample at a minimum 
concentration of 30ng/μl. 66 of the original 722 available samples yielding 
concentrations less than 30ng/μl were therefore excluded, leaving 656 eligible 
participants.  
 
For this phase of the study, participants were chosen for case and control groups to 
maximize phenotypic differences between groups. Selection for case and control 
groups depended on participants’ MMSE performance at year 9 and the magnitude of 
their cognitive decline over the preceding 9 years (fig. 2.1). 50 case and 50 control 
individuals were selected to achieve a power of .90 to detect a 20% alteration in 
transcription abundance between individuals in case and control groups.  
 
Categorisation into case and control groups excluded any confounding individuals who 
exhibited either 1) impaired but stable cognitive function over the 9 years of follow-up 
or 2) significant cognitive decline within the cognitive maintenance range. These 
exclusions ensured the provision of clearly distinct categories of significant cognitive 
decline. Individuals were not excluded on the basis of any additional medical, 
medication or lifestyle information as existing studies present either no evidence or 
inconclusive evidence for any influence for these factors on cognitive decline. 
 
Participants in the control group scored at least 28 MMSE points at time of blood draw 
(their year 9 interview) and exhibited no decline in MMSE score over the preceding 9 
years. Participants in the case group achieved a year 9 MMSE score of no more than 24 
points, and exhibited at least a 5 point decline in MMSE score over the preceding 9 
years, indicating significant cognitive decline (fig. 2.1). 
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Figure 2.1 Algorithm by which individuals were selected for case and control groups.  
50 case and 50 control participants were selected using this algorithm, which assessed 
each participant for quality of RNA sample, age, sex, MMSE score at baseline and 
subsequent MMSE score 9 years later 
More men than women maintained their MMSE above 28 points at year 9. To further 
discriminate between these highest functioning individuals, only men with a MMSE of 
at least 29 at year 9 were considered for qRT-PCR. To select 50 individuals from the 31 
men and 26 women eligible in the control group, individuals were ranked according to 
the highest recorded level of education they received, and individuals from each rank 
were excluded to maintain the original distribution of educational achievement across 
each group.  
 
2.9.8 Reverse transcription 
Reverse transcription was performed using the SuperScript® VILO™ cDNA Synthesis Kit 
(Invitrogen, Paisley, UK) according to the manufacturers’ instructions. The Synthesis Kit 
consists of 10X SuperScript® Enzyme Mix (SuperScript® III Reverse Transcriptase, 
recombinant ribonuclease inhibitor and a proprietary helper protein) and 5X VILOTM 
Reaction Mix (random primers, dNTPs and MgCl2 in buffer solution). These reagents 
were stored at -20:C when not in use, then thawed on ice and centrifuged before use. 
Similarly, aliquotted RNA samples were stored at -80:C when not in use, then thawed 
on ice and microcentrifuged before addition to solution. Reverse transcriptions were 
performed in 13 batches of maximum 8 samples. 
 
For each reverse transcription, Enzyme mix, Reaction mix and sterile, RNase-free 
distilled water were combined at ratio 1:2:6.5 to a total volume of 161.5μl. Reagents 
were inverted and centrifuged, and the mix divided into 0.2ml thin wall PCR tubes to 
an individual volume of 19μl. 1μl total RNA (minimum concentration 30ng/μl RNA) 
from each sample aliquot was then added to its reaction tube to a total volume of 
20μl. Tubes were incubated at 25:C for 10 minutes, 42:C for 60 minutes and 85:C for 5 
minutes to allow cDNA synthesis. Resulting cDNA samples were either immediately 
used for qPCR or stored at -20:C. 
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2.9.9 Real-time quantitative PCR  
Real-time quantitative PCR (qPCR) was carried out using TaqMan® Low Density Arrays 
(TLDA) on the ABI Prism 7900HT system using the ABI Prism 7900HT Sequence 
Detection System software (Applied Biosystems, California, USA). TaqMan® Low 
Density Arrays (TLDAs) are custom 384-well microfluidic cards pre-loaded with 
TaqMan® Gene Expression Assays selected from the Applied Biosystems inventory 
(https://products.appliedbiosystems.com). TaqMan® Gene Expression Assays contain 
two unlabelled PCR primers and a carboxyfluorescein (FAM) dye-labelled TaqMan 
probe for each selected sequence. 13 TLDA plates were designed, stored at 2oC and 
used for this analysis of 100 samples.  
 
For this experiment, two genes of interest were quantified (BIN1 and PVRL2) alongside 
2 endogenous housekeeping genes (PPIA and GAPDH). The inventoried assay used for 
quantifying BIN1 was TaqMan® Gene Expression Assay Hs00184913_m1, whose probe 
anneals to an exon-exon boundary spliced into all 10 BIN1 RefSeq transcripts. The 
probe for PVRL2 in assay Hs01071562_m1 anneals to an exon-exon boundary present 
in both annotated PVRL2 isoforms. 
 
In preparation for cDNA amplification, 20μl cDNA from each reverse transcription 
reaction was thawed and microcentrifuged. 50μl TaqMan® Universal PCR Master Mix 
(containing AmpliTaq Gold DNA Polymerase, dNTPs with dUTP, and optimised buffer 
components, stored at 2oC) was added to each cDNA sample, and 30μl sterile, RNAse 
free water added to a final volume of 100μl. Reagents were mixed and centrifuged, 
ensuring no air bubbles had formed in the tubes. 100μl of each sample-specific 
reaction mix was then loaded into a TLDA fill reservoir in preparation for amplification 
in batches of 8 samples. After sample loading, TLDA cards were centrifuged (1000rpm 
for 2 x 1 minute) to distribute reaction mix from fill reservoirs into reaction wells. 
Reservoirs were checked manually to ensure equal distribution of reaction mixes had 
taken place. Cards were sealed, and the fill consumable portion of the card removed 
before insertion into the instrument. Plate configuration and array details were taken 
from the TLDA-specific Applied Biosystems array CD. Cycling conditions were 
programmed to 50oC for 2 minutes, 95oC for 10 minutes, followed by 50 cycle repeats 
of 97oC for 30 seconds and 59.7oC for 1 minute.  
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After PCR amplification, SDS software determined an arbitrary threshold for detection 
of fluorescence from amplified products above background. The PCR cycle (maximum 
cut-off 50) at which a transcript’s probe fluorescence signal crossed this threshold was 
determined as the transcript’s cycle threshold (CT), giving a quantitative endpoint 
measure of amplification. Transcript CT was inversely related to the quantity of 
amplified product in the reaction well. Raw CT values were used for quality control 
(QC) steps and for relative quantification analysis. 
 
2.9.9.1 Quality control 
Wells in which no amplification product was detected above the threshold of 
background noise after 50 cycles were removed before quantification analysis. 
Technical outliers were also removed before analysis: if the average CTs calculated 
from triplicate reactions for each transcript had a standard deviation of greater than 
0.5, the well contributing the CT furthest deviating from the mean of the three wells 
was removed from analysis. 
 
2.9.10 Comparative Ct method 
Data was analysed manually in Microsoft Excel using the comparative (ΔΔCt) method 
(Livak and Schmittgen, 2001). Use of this relative quantification method allowed data 
to be presented as standardised ‘fold-change’ results between samples or sample 
groups. To apply the ΔΔCt method, average CT for each transcript in each sample was 
first calculated, and technical outliers removed as detailed above.  
 
Normalisation to an internal control CT for each sample was then carried out to correct 
for varying amplification efficiency between samples. For each sample, the mean CT 
across every control probe well was calculated to produce a mean internal control CT 
for that sample. For each probe, mean transcript CT  –  mean internal control CT was 
calculated and termed ΔCT. Normalisation to a calibrator ΔCT value for each probe was 
then carried out to standardize probe expression across samples. For each probe, the 
mean ΔCT across all samples in the control group was calculated, and this ΔCT taken as 
a calibrator ΔCT. ΔCT for each transcript in each sample – calibrator ΔCT =  ΔΔCT. ΔΔCT 
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was therefore normalized by gene and by sample. Fold change in probe expression 
relative to the mean probe expression across all control samples was determined by 
the formula 2-ΔΔCT. The equation refers to the 2-fold change in product seen per PCR 
cycle in a 100% efficient reaction: 2-ΔΔCT represents the number of doubling cycles of 
amplification occurring between reference Ct and sample Ct. 
 
2.9.10.1 Quality control 
The mean and standard deviation of the relative quantification (RQ) values for each 
gene were calculated, and results excluded if their RQ value lay +/- 3 standard 
deviations from the RQ mean for each gene.  
 
2.9.11 Association analysis 
2-ΔΔCT values for probe transcripts across case and control groups were analysed for 
association with cognitive decline using the binary phenotype described in section 
2.9.7 in a logistic regression model adjusted for the following potential confounding 
factors: age in years (as a continuous variable), gender, highest level of education 
received (in five categories: none, elementary, secondary, high school, and 
university/professional), lifetime pack-years smoked (in four categories: none, less 
than 20 years, 20 to 39 years, and 40 plus years), blood leukocyte type percentages 
(neutrophil, lymphocyte, monocyte and eosinophil percentages as continuous 
variables), and study site (categorical as either a rural setting, Greve in Chianti, or an 
urban setting, Bagno a Ripoli). 
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Chapter 3 Results: Genome-wide gene expression 
 
3.1 Whole blood RNA samples  
Whole blood samples were collected from 733 individuals who attended for 
examination 9 years after enrolment. After RNA extraction, 722 samples passed RNA 
yield, integrity and purity quality control steps. Mean RNA concentration after 
purification was 77.88 ng/μl (SD 33.94, range 4.11-195.2), and the mean yield 6μg. 
Mean A260/A280 ratio was 2.30 (SD 0.27, range 0.76-4.82), suggesting low protein 
contamination of samples. Only two samples had an unacceptable A260/A280 ratio <1.8.  
 
3.2 Expression profiling  
3.2.1 Transcripts 
After correction for background effects, detection p-value calculation, calibration to 
housekeeping genes, data normalization and outlier exclusion, 16,571 of the original 
47,000 microarray transcripts gave reliable signals above background (p<0.01) in >5% 
of the sample population. Expression data from these 16,571 transcripts was therefore 
eligible for association analyses.  
 
3.2.2 Samples 
Expression data were available for n=707 individuals after exclusions due to microarray 
quality control steps. Analysis of cohort mean signal intensity across all probes resulted 
in further exclusion of 9 samples whose mean signal intensities across all probes were 
either missing or ± 3 standard deviations from the cohort mean, or samples in which 
the proportion of expressed probes was more than 3 SD below the cohort mean. 698 
samples were therefore eligible for consideration for transcriptome-wide, gene 
pathway and eQTL analysis. Of these 698 samples, 691 individuals had MMSE 
performance recorded at baseline and year 9 and were therefore eligible for analysis 
of gene expression associations with cognitive decline. 
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Table 3.1 Associations between cognitive decline and participant demographics. 
Participants’ age, sex, educational attainment and APOE haplotype, and these factors’ 
odds ratio for cognitive decline (unadjusted) are given in the table alongside the 
number of tests performed (#) and the p-value of each odds ratio. Cognitive decline is 
here defined categorically as a decline of at least 5 MMSE points to a final score of no 
more than 24 points at year 9, as described in section 2.10.7. Significant associations 
are starred  
 
 Odds ratio for 
cognitive decline 
# p-value 
Increasing age 1.09** 691 <0.001 
Female sex 1.90* 691 0.026 
Higher educational attainment 0.09** 691 <0.001 
Presence of at least one copy of APOE 
allele ε4 
1.36 691 0.070 
* Significant at the p=0.05 level 
** Significant at the p=0.01 level 
3.3 Cognitive phenotype 
691 individuals with high-quality RNA and microarray data had their MMSE score 
recorded at baseline and at the time of RNA collection, 9 years later. At baseline, 
17.8% of these individuals demonstrated cognitive impairment (MMSE score 24 or 
less). At year 9, this percentage of cognitively impaired individuals had risen to 26.5%.  
 
In the cohort (n=691), cognitive decline was found to have a statistically significant 
association with age, sex and educational attainment (table 3.1). These demographics 
were therefore included as covariates in regression analyses. Cognitive decline did not 
have a statistically significant association with presence of the APOE ε4 allele. 
 
Higher education levels were significantly correlated with male gender (Spearman’s 
rho=0.18, p<0.0001). 
75 
3.4 Cognitive performance analysis 
3.4.1 Participant selection 
The first expression-phenotype analysis of the available data was conducted to analyse 
probe expression levels in association with individuals’ MMSE performance at the time 
of blood draw for RNA collection. 691 participants completed their MMSE at time of 
blood draw. All of these individuals had QC-passed microarray data and were therefore 
eligible for phenotype association analysis with each of the 16,571 QC-passed 
expression probes.  
 
3.4.2 Statistical analysis 
A multiple linear regression model was used to analyse the statistical significance of 
expression associations with cognitive performance. Expression of each probe (as a 
continuous trait) was used as the independent variable, and MMSE performance at 
time of blood draw (across the range 0 to 30) as the continuous dependent variable. 
No participant exclusions were applied based on cognitive change over time. The 
analysis included adjustments for potential microarray amplification and hybridisation 
batch effects, study site, age, sex, education, leukocyte percentages, and pack-years 
smoked, as detailed in section 2.7.1. Probes’ expression intensity were taken to have a 
statistically significant association with cognitive performance if they achieved a 
nominal p-value<0.05 and a q-value <0.1. The analysis was powered to detect 
expression differences of <0.25 SD for the 16,571 investigated probes. 
 
One gene, CCR2, tagged by probe ilmn_1774761, was found to have a statistically 
significant association with MMSE performance at year 9 (coefficient -0.00415, CIs: -
0.0056 to -0.0027, p=5.09x10-6, q=0.076) (table 3.2). CCR2 encodes a monocyte 
chemotaxis chemokine receptor. 
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Table 3.2 Probe expression associations with cognitive performance. The top 10 
probes associated with MMSE score at blood draw are presented (ordered by p-value).  
Genes marked by each probe, the number of tests performed, associations’ coefficient 
and standardised coefficient (“beta”), the confidence intervals of each coefficient and 
associations’ p- and q-values are also presented 
 
Probe ID Gene # Coefficient Beta 95% CIs p-value q-value 
ilmn_1774761 CCR2 691 -0.0042* -0.1616 -0.0056 -0.0027 5.09E-06 0.0762 
ilmn_2374362 FAM108B1 691 -0.0015 -0.1709 -0.0021 -0.0009 2.72E-05 0.2038 
ilmn_1791912 SIDT2 691 0.0052 0.1475 0.0030 0.0074 0.0001 0.3556 
ilmn_1758457 TBC1D16 691 0.0008 0.1473 0.0005 0.0011 0.0001 0.3610 
ilmn_1796094 CD36 691 -0.0044 -0.1486 -0.0063 -0.0025 0.0002 0.3808 
ilmn_1693949 UNQ1944 691 0.0011 0.1153 0.0006 0.0015 0.0002 0.3903 
ilmn_1724266 LYPD2 691 0.0017 0.1382 0.0009 0.0025 0.0003 0.4181 
ilmn_1772821 KIAA1671 691 -0.0015 -0.1561 -0.0022 -0.0008 0.0004 0.4300 
ilmn_2313434 TCP1 691 0.0013 0.1476 0.0007 0.0019 0.0004 0.4326 
ilmn_2393573 RASSF1 691 -0.0019 -0.1073 -0.0027 -0.001 0.0004 0.4342 
* Significant at the p=0.05, q=0.1 level 
 
 
3.4.2.1 Quantile-quantile plot 
A quantile-quantile graph was plotted to compare the quantile distribution of p-values 
(on a -log10 scale) generated by the analysis to the quantile distribution of an equal 
number of randomly generated p-values (fig. 3.1). This allowed comparison of the 
observed p-value distribution and the distribution that would be expected if p-values 
had been generated by chance.  
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Figure 3.1 Quantile-quantile plot for gene expression analysis of cognitive 
performance. The quantile-quantile plot for the global expression analysis of MMSE 
performance at blood draw is shown. The actual p-values (-log10) obtained are given on 
the y-axis, plotted against random p-values (-log10) on the x-axis. The line y=x 
(observed=expected) is plotted as a dotted line. The graph shows potential deviations 
to the p-value distribution that might not be expected by chance. The majority of 
associations do not vary far from the line observed=expected. Deviating furthest from 
the line y=x is the p-value (5.09*10-6) of the statistically significant association between 
CCR2 expression and cognitive performance (circled) 
 
 
 
The plot demonstrates a skew from the line observed=expected, illustrating that the p-
values generated by this analysis were lower than the p-values expected by chance. 
The outlying observed –log10 p-value of 5.09 is the p-value for CCR2’s expression 
association with cognitive performance. The plot demonstrates that MMSE 
performance was not associated with large scale disruption to gene expression levels 
beyond that expected by chance.  
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Figure 3.2 Participants’ cognitive decline over 9 years. The difference between 
individuals’ MMSE performance at baseline and performance 9 years later is presented 
in the histogram. 9-year MMSE performance change is plotted on the x-axis (units = 
MMSE points score), and the number of individuals who declined by, or gained, each 
number of points is plotted on the y-axis. 
 
3.5 Cognitive decline analysis 
3.5.1 Participant selection  
The second expression-phenotype analysis of the available data was conducted to 
analyse gene expression in association with participants’ cognitive change over 9 
years. 691 individuals had QC-passed microarray data and MMSE score recorded at 
both baseline and blood draw: these were therefore eligible for analysis of cognitive 
decline in association with each of the 16,571 QC-passed expression probes. 
 
Among the 691 eligible participants, mean MMSE at baseline was 26.89 (SD 2.57) and 
mean MMSE 9 years later, at time of blood draw, was 25.58 (SD 5.66). Median MMSE 
change over the 9 years was 0 points, interquartile range -2 to 1 points, range -27 to 7 
points (fig. 3.2). 
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Table 3.3 Probe expression associations with cognitive decline over 9 years. The top 
10 probes associated with MMSE performance change between baseline and blood 
draw are presented (ordered by p-value).  Genes marked by each probe, the number 
of tests performed, associations’ coefficient and standardised coefficient (“beta”), the 
confidence intervals of each coefficient and associations’ p- and q-values are also 
presented 
 
Probe ID Gene # Coefficient Beta 95% CIs p-value q-value 
ilmn_1774761 CCR2 691 -0.0040 -0.1616 -0.0056 -0.0024 5.49E-05 0.7001 
ilmn_2374362 FAM108B1 691 -0.0015 -0.1709 -0.0022 -0.0009 0.0001 0.7001 
ilmn_1796094 CD36 691 -0.0047 -0.1486 -0.0067 -0.0026 0.0002 0.7001 
ilmn_1761941 C4orf18 691 -0.0017 -0.144 -0.0024 -0.0009 0.0003 0.7001 
ilmn_2313434 TCP1 691 0.0015 0.1476 0.0008 0.0022 0.0003 0.7001 
ilmn_1712684 FAM20C 691 -0.0011 -0.1538 -0.0015 -0.0006 0.0003 0.7001 
ilmn_1866887 BX537605 691 -0.0011 -0.1576 -0.0016 -0.0006 0.0003 0.7001 
ilmn_1772821 KIAA1671 691 -0.0016 -0.1561 -0.0023 -0.0008 0.0006 0.7001 
ilmn_1703314 KLHL36 691 0.0013 0.1566 0.0007 0.0020 0.0006 0.7001 
ilmn_1789751 MFSD1 691 -0.0039 -0.131 -0.0058 -0.0020 0.0006 0.7001 
 
3.5.2 Statistical analysis 
Multiple linear regression analysis was used to investigate the association between 
probe expression and cognitive decline in the 691 eligible individuals, using probe 
expression intensity as the independent variable, MMSE performance change over 9 
years as the dependent variable, and adjusting for the potential confounders detailed 
in section 2.7.1.  Associations were taken to be significant if they achieved a nominal p-
value <0.05 and a q-value <0.1. 
 
After adjusted analysis, no probes were found to have a significant association with 
cognitive decline at q-value <0.1. The probe that most closely neared significant 
association was CCR2 (coefficient -0.004, Cis: -0.0056 to -0.0024, p-value 5.49x10-5, q-
value 0.7001) (table 3.3).  
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Figure 3.3 Quantile-Quantile plot for gene expression analysis of cognitive decline. 
The quantile-quantile plot for the genome-wide expression analysis of MMSE 
performance change between baseline and blood draw 9 years later is shown. The 
actual p-values (-log10) obtained are given on the y-axis, plotted against random p-
values (-log10) on the x-axis. The line y=x (observed=expected) is plotted as a dotted 
line. No associations vary from the line observed=expected 
 
3.5.2.1 Quantile-quantile plot 
A quantile-quantile plot of p-values generated by this analysis (observed) against p-
values generated by chance (expected) demonstrated that cognitive decline analysis p-
values were very similar to the p-values expected due to chance (fig. 3.3).  
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Chapter 4 Inflammatory subset analysis  
 
4.1 Reason for subset analysis 
Current literature suggests a role for peripheral inflammation in cognitive decline, and 
genome-wide gene expression analysis has here identified an inflammatory gene 
(CCR2) significantly associated with cognitive performance in an analysis powered to 
identify associations of moderate-to-large effect size. To follow up this positive finding, 
further analyses were conducted to focus in on the inflammatory subset of genes 
expressed by peripheral leukocytes. These analyses were performed to understand 
whether further inflammatory genes had a significant association with cognitive 
performance of too small an effect size to attain significance in genome-wide analyses. 
The smaller subset of genes tested in these analyses decreased the risk of type II error 
inherent to transcriptome-wide analyses of gene expression. 
 
4.2 Selection of inflammatory genes for analysis 
44 inflammatory gene sets were identified. 2031 annotated expression probes were 
present in one or more of these inflammatory gene sets. Of these probes, 1228 were 
included on the Illumina Human_HT12 v3 microarray and passed processing QC steps 
across the InCHIANTI samples (table S1 in appendix). Expression of these 1228 probes 
was therefore analysed for statistically significant association with cognitive 
performance and cognitive decline. 
 
4.3 Cognitive performance analysis 
Probe expression associations with the continuous variable of cognitive performance 
at year 9 were analysed using a multiple linear regression model accounting for 
potential microarray amplification and hybridisation batch effects, study site, 
participants’ age, sex, education, leukocyte percentages, and pack-years smoked, as 
detailed in section 2.6.2. Associations were taken to be statistically significant if they 
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achieved a nominal p-value <0.05 and a q-value <0.1. The analysis was powered to 
detect standardised expression differences of <0.22 SD for the inflammatory subset. 
 
Cognitive performance analysis using this inflammatory subset again identified CCR2 as 
having a significant association with cognitive performance (coefficient -0.00415, CIs -
0.00564 to -0.00267, p-value 5.09x10-6, q-value 0.00298) (table 4.1). Subset analysis 
identified no additional significant inflammatory gene associations with cognitive 
performance. 
 
Table 4.1 Inflammatory subset probe expression associations with cognitive 
performance. The top 10 inflammatory-related probes (ordered by q-value, total 
n=1228) associated with MMSE performance at time of blood draw are given in the 
table with the name of the gene marked by each probe, the number of tests 
performed, associations’ coefficient and standardised coefficient (beta), and 
associations’ 95% confidence intervals, p-values and q-values 
 
Probe ID Gene # Coefficient Beta 95% CIs p-value q-value 
ilmn_1774761 CCR2 691 -0.00415* -0.1616 -0.00564 -0.00267 5.09E-06 0.00298 
ilmn_2366212 CD79B 691 0.00828 0.1267 0.004018 0.01254 0.001461 0.2319 
ilmn_1677440 ATP6AP2 691 -0.00546 -0.1194 -0.00843 -0.00249 0.002557 0.26203 
ilmn_2276996 CCR2 691 -0.00089 -0.1071 -0.00138 -0.0004 0.002789 0.26586 
ilmn_1785439 CD79B 691 0.00422 0.1239 0.001824 0.006622 0.003911 0.27874 
ilmn_1710017 CD79B 691 0.00448 0.1302 0.001932 0.007026 0.003949 0.27907 
ilmn_1764396 HDAC4 691 -0.00108 -0.0725 -0.00171 -0.00044 0.005279 0.28773 
ilmn_1763875 ABCF1 691 0.0022 0.0842 0.000885 0.003511 0.006076 0.29125 
ilmn_1738767 PLP2 691 -0.00119 -0.078 -0.00191 -0.00047 0.006468 0.29269 
ilmn_1747227 ADORA1 691 0.00079 0.1412 0.000309 0.001272 0.007126 0.29477 
* Significant at the p=0.05, q=0.1 level 
 
The quantile-quantile plot of p-values generated by this analysis (-log10 scale) 
compared to randomly generated p-values illustrates that the results of this analysis 
have lower p-values than would have been expected by chance, although only CCR2’s 
association reaches statistical significance (fig. 4.1). 
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Figure 4.1 Quantile-quantile plot for inflammatory subset gene expression analysis of 
cognitive performance The quantile-quantile plot for the inflammatory subset 
expression analysis of MMSE performance at blood draw is shown. The actual p-values 
(-log10) obtained are given on the y-axis, plotted against random p-values (-log10) on 
the x-axis. The line y=x (observed=expected) is plotted as a dotted line. The graph 
shows potential deviations to the p-value distribution that might not be expected by 
chance. The significant p-value (5.09*10-6) of the association between CCR2 expression 
and cognitive performance is circled 
 
 
4.4 Cognitive decline analysis 
Associations between inflammatory-related probes and preceding 9-year cognitive 
decline were analysed using a multiple linear regression model adjusting for potential 
microarray amplification and hybridisation batch effects, study site, participants’ age, 
sex, education, leukocyte percentages, and pack-years smoked, as detailed in section 
2.6.2. Associations were taken to be statistically significant if they achieved a nominal 
p-value <0.05 and a q-value <0.1. A significant association was identified between 
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CCR2 expression abundance and preceding 9-year cognitive decline (coefficient -
0.00399, CIs -0.00561 to -0.00238, p-value 5.49x10-5, q-value 0.0333) (table 4.2). No 
additional statistically significant associations were identified between inflammatory-
related probes’ expression and cognitive decline (table 4.2, figure 4.2).  
 
Table 4.2 Inflammatory subset probe expression associations with cognitive decline 
over 9 years. The top 10 inflammatory-related probes (ordered by q-value, total 
n=1228) associated with MMSE performance change between baseline and blood 
draw are given in the table with the name of the gene marked by each probe, the 
number of tests performed, associations’ coefficient and standardised coefficient 
(beta), and associations’ 95% confidence intervals, p-values and q-values 
 
Probe ID Gene # Coefficient Beta 95% CIs p-value q-value 
ilmn_1774761 CCR2 691 -0.00399* -0.1616 -0.00561 -0.00238 
5.49E-
05 
0.0333 
ilmn_2366212 CD79B 691 0.00873 0.1267 0.004084 0.013367 0.00207 0.3051 
ilmn_1710017 CD79B 691 0.00517 0.1302 0.002402 0.007946 0.00223 0.3101 
ilmn_1677440 ATP6AP2 691 -0.00588 -0.1194 -0.00911 -0.00265 0.00286 0.3250 
ilmn_1747227 ADORA1 691 0.00094 0.1412 0.000417 0.001465 0.00324 0.3317 
ilmn_1737398 PTPLAD1 691 -0.00117 -0.1251 -0.00182 -0.00052 0.00329 0.3324 
ilmn_1785439 CD79B 691 0.00458 0.1239 0.001966 0.007191 0.00408 0.3486 
ilmn_1682312 CYBB 691 -0.00251 -0.0925 -0.00403 -0.001 0.00652 0.3772 
ilmn_1811049 POU2AF1 691 0.00119 0.1205 0.00047 0.001916 0.00681 0.3794 
ilmn_1771333 CD47 691 -0.00354 -0.1103 -0.00568 -0.00139 0.00686 0.3797 
* Significant at the p=0.05, q=0.1 level 
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Figure 4.2 Quantile-quantile plot for inflammatory subset gene expression analysis of 
cognitive decline over 9 years. The quantile-quantile plot for the inflammatory subset 
expression analysis of MMSE performance change between baseline and blood draw, 9 
years later, is shown. The actual p-values (-log10) obtained are given on the y-axis, 
plotted against random p-values (-log10) on the x-axis. The line y=x 
(observed=expected) is plotted as a dotted line. The graph shows potential deviations 
to the p-value distribution that might not be expected by chance. The significant p-
value (5.49*10-5) of the association between CCR2 expression and cognitive 
performance is circled 
86 
Chapter 5 Results: Analysis by gene pathway 
5.1 Compression of expression data into constituent genes 
Using gene symbols and the Illumina annotation file, expression of the 16,571 eligible 
microarray probes was collapsed to represent expression of the 12,357 represented 
genes.  
 
5.2 Pathways chosen for analysis 
642 of the 1454 gene sets annotated in the gene ontology catalogue on the MSigDB 
website (http://www.broadinstitute.org/gsea/msigdb/index.jsp) were eligible for gene 
pathway association analysis. All 691 individuals with adequate microarray data and 
recorded MMSE scores at baseline and blood draw were eligible for gene pathway 
analysis. 
 
5.3 Association analysis 
Gene set enrichment analysis (GSEA) software from the Broad Institute was used to 
rank the selected 642 gene pathways’ associations with the continuous phenotypes of 
cognitive performance at blood draw and cognitive decline over the 9 years between 
baseline and blood draw in 691 participants. Gene sets with a p-value<0.01 and q-
value <0.1 were considered to have a significant association with phenotype. 
 
After gene set enrichment analysis, no gene sets were found to have a significant 
association with either cognitive performance or cognitive decline at the q-value <0.1 
level (tables 5.1 and 5.2). 
 
 
 
 
 
87 
Table 5.1 Associations between gene pathways and cognitive performance. The top 
10 associations between gene pathways and MMSE performance at blood draw are 
given. No associations are significant at the p<0.01 q<0.1 level. Also given are gene set 
size, enrichment score (ES), enrichment score p-value and q-value 
 
Gene pathway Size N ES p-value q-value 
Aromatic compound metabolic process 17 691 -1.820 0.000 0.846 
Regulation of DNA metabolic process 29 691 -1.743 0.008 0.947 
T cell activation 27 691 -1.563 0.031 1 
Cellular defense response 38 691 -1.524 0.035 1 
Anatomica structure formation  27 691 -1.548 0.036 1 
Positive regulation of lymphocyte activation  15 691 -1.581 0.039 1 
Protein kinase binding 48 691 1.413 0.040 1 
RNA export from nucleus 17 691 -1.516 0.045 1 
Kinase binding 55 691 1.400 0.046 1 
DNA recombination 32 691 -1.501 0.047 1 
 
 
Table 5.2 Associations between gene pathways and cognitive decline. The top 10 
associations between gene pathways and MMSE change over 9 years are given. No 
associations are significant at the p<0.01 q<0.1 level. Also given are gene set size, 
enrichment score (ES), enrichment score p-value and q-value 
 
Gene pathway Size N ES p-value q-value 
Regulation of DNA metabolic process 29 691 -1.875 0.002 0.421 
RNA export from nucleus 17 691 -1.673 0.006 0.997 
Carboxylesterase activity 16 691 -1.748 0.014 0.760 
Aromatic compound metabolic process 17 691 -1.640 0.020 0.988 
Protein kinase binding 48 691 1.533 0.025 1 
Phosphoric diester hydrolase activity 17 691 1.538 0.035 1 
Regulation of gene expression epigenetic 26 691 -1.515 0.036 1 
Cell-cell adhesion 34 691 -1.447 0.039 1 
Kinase binding 55 691 1.466 0.041 1 
Detection of stimulus  17 691 1.559 0.044 1 
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Chapter 6 Results: eQTL analysis 
6.1 Genotyping 
No published genome-wide association studies identify any SNPs which have a 
significant association with cognitive decline. In previously published work, 14 SNPs 
have been found to have a GWAS-significant association (p<1x10-8) with late-onset 
Alzheimer disease, a primary contributor to the functional phenotype of cognitive 
decline.  10 of these SNPs were directly genotyped in the InCHIANTI cohort (rs597668, 
rs744373, rs11136000, rs2075650, rs3851179, rs11767557, rs157580, rs610932, 
rs3764650, rs1562990). The remaining 4 SNPs were genotyped indirectly (rs6656401, 
rs9349407, rs4938933, rs3865444). 613 individuals with adequate microarray data 
were genotyped. 
 
6.2 eQTL identification  
Searches of the University of Santa Cruz Genome Browser 
(http://genome.ucsc.edu/cgi-bin/hgGateway) identified 197 unique genes within 
500kb of any of the 14 relevant SNPs; approximately 15 genes were local to each SNP. 
QC-passed microarray expression data is held for 84 of these 197 genes. Using multiple 
linear regression analysis, five SNPs were found to have a significant association with 
expression abundance of one of these 84 local genes at the p<0.001, q<0.001 level, 
and were eligible for eQTL analysis. These SNPs were rs744373 for BIN1, rs610932 for 
MS4A6A, rs4938933 for MS4A6A, rs1562990 for MS4A6A and rs157580 for PVRL2 
(association coefficients and p-values given in table 6.1; also see figure 6.1.a-e). The 
two eQTLs most significantly associated with gene expression abundance (rs744373 
and rs610932) had significant associations with expression abundance of multiple 
probes tagging each of their target genes.  
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Table 6.1 Significant associations between eQTL genotypes and probe expression 
levels. The eQTL SNPs significantly associated (p<0.001, q<0.001) with Illumina probe 
expression are presented (ordered by p-value) alongside the gene marked by each 
probe, the number of tests performed (N) and the coefficient, p-value and q-value of 
each significant association 
 
SNP Probe ID Gene N Coefficient p-value q-value 
rs744373 ilmn_2309245 BIN1 613 0.05313 1.11E-09 2.64E-09 
rs610932 ilmn_1721035 MS4A6A 613 -0.07663 1.60E-09 1.15E-08 
rs744373 ilmn_1674160 BIN1 613 0.06549 2.35E-08 2.78E-08 
rs4938933 ilmn_1721035 MS4A6A 613 -0.06917 4.69E-08 3.53E-07 
rs1562990 ilmn_1721035 MS4A6A 613 -0.06872 5.16E-08 4.10E-07 
rs157580 ilmn_1718303 PVRL2 613 0.02072 3.42E-06 5.82E-05 
rs610932 ilmn_1797731 MS4A6A 613 -0.04741 7.32E-05 0.000263 
 
Figure 6.1a 
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Figure 6.1.b 
 
Figure 6.1c 
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Figure 6.1.d 
 
 
Figure 6.1.e 
 
Figure 6.1 Boxplots of probe expression intensity by genotype at significant eQTLs. The 
boxplots show the spread of probe expression intensity (relative units) as plotted on the 
y-axis against genotype of the associated eQTL on the x-axis. On each graph the first 
boxplot represents expression intensities across individuals homozygous for the major 
allele, the second boxplot represents heterozygous individuals, and the third boxplot 
represents individuals homozygous for the minor allele at each eQTL. Boxes represent the 
25th to 75th percentiles of probe expression intensity, central bars represents median 
expression intensity, and whiskers represent the 5th and 95th percentiles of expression 
intensity. Dots represent expression intensity outliers. For eQTLs associated with 
expression intensity of two probes marking the same gene (rs744373 for BIN1 and 
rs610932 for MS4A6A), boxplots of only the most significantly associated probe are given. 
Figures .a-.e plot expression of a. ilmn_2309245 (BIN1) against genotype at rs744373; b. 
ilmn_1721035 (MS4A6A) against genotype at rs610932; c. imn_1721035 (MS4A6A) 
against genotype at rs4938933; d. ilmn_1721035 (MS4A6A) against genotype at 
rs1562990; e. ilmn_1718303 (PVRL2) against genotype at rs157580. 
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Table 6.2 Significant SNP-expression associations at global expression analysis.  The 
eQTL SNPs significantly associated (p<0.001, q,0.001) with Illumina probe expression at 
global expression analysis are presented (ordered by p-value) alongside the gene marked 
by each probe, the number of tests performed (#) and the coefficient, p-value and q-value 
of each significant association 
SNP Probe ID Gene # Coefficient p-value q-value 
rs610932 ilmn_1721035 MS4A6A 613 -0.07692 1.32E-09 0.00002 
rs744373 ilmn_2309245 BIN1 613 -0.00503 2.87E-08 0.00034 
rs4938933 ilmn_1721035 MS4A6A 613 -0.06888 5.41E-08 0.00072 
rs1562990 ilmn_1721035 MS4A6A 613 -0.06782 6.75E-08 0.00087 
 
6.3 Verification by genome-wide eQTL analysis 
On performing a global eQTL analysis to analyse associations between identified eQTLs 
and any of the 16,571 probes on the chip (and thus necessitating a much higher 
multiple testing correction), the 4 most significant SNP-gene associations described in 
section 6.2 remained significant at the p<0.001, q<0.001 level (table 6.2). The 
association between SNP rs157580 and expression of PVRL2 became statistically 
insignificant under this more stringent analysis.  
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6.4 eQTL location relative to target genes 
rs744373 is located at chr2:127894614 (q14.3) in an intergenic region 30kb upstream 
of BIN1. All three MS4A6A-associated SNPs lie in a LD block encompassing the MS4A 
gene cluster which includes 6 genes in membrane-spanning 4-domain subfamily A: 
MS4A2, MS4A3, MS4A6A, MS4A4E, MS4A6A and MS4A6E. rs610932 is located within 
the 3’ untranslated region (UTR) of MS4A6A, while rs1562990 and rs4938933 lie, 
respectively, 72kb and 83kb upstream of its transcription start site. These two SNPs are 
located in an intron of putative gene HQ447086, which is read in the opposite direction 
to MS4A6A. Interestingly, SNP rs157580 is located in an intron of annotated gene 
TOMM40, 3kb from the 5’ end of PVRL2. 
 
6.5 Proxy identification 
From the results of the eQTL search, it was clear that the three SNPs near MS4A6A had 
a very similar effect on MS4A6A expression, particularly rs4938933 and rs1562990 
whose beta coefficients between genotype and MS4A6A expression are almost 
identical (-0.0689 for rs4938933 and -0.0678 for rs1562990; see figure 6.1.c,d). It is 
possible that the associations were so similar because the two SNPs are in perfect 
linkage disequilibrium with each other e.g. genotype at one SNP is a perfect predictor 
of genotype at its partner SNP. In addition, identified eQTLs could potentially act as 
proxies for SNPs not genotyped by the Illumina HumanHap550 BeadChip. The SNAP 
server (www.broad.mit.edu/mpg/snap) was therefore used to identify whether the 
five identified SNPs (rs744373, rs4938933, rs1562990, rs610932 and rs157580) acted 
as proxies for any alternative SNPs. Proxy identification for an identified eQTL could 
indicate that identified eQTLs were effectively tagging functional variants, rather than 
themselves being causal in expression abundance variation. True eQTLs would need to 
be identified among proxies by functional characterisation at each locus. 
 
The SNAP server identified proxy SNPs at the specified r2=1 (perfect linkage 
disequilibrium) with identified eQTLs using data from the 1000 Genomes database 
(Consortium, 2010). rs1562990 and rs4938933 were found to act as proxies for each 
other and for two additional SNPs: rs7108663 and rs4938931 (table 6.3). rs744373 had 
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Table 6.3 Proxy SNPs for eQTLs.  SNPs in r2=1 with identified eQTLs, as identified by the 
1000 Genomes project, are presented alongside the distance between eQTL and proxy, 
and the chromosomal location of each proxy. rs1562990 and rs4938933 function as 
proxies for each other 
eQTL Proxy Distance r2 Proxy location 
rs1562990 rs4938931 3526 1 chr11:59783189 
rs1562990 rs7108663 5055 1 chr11:59784718 
rs1562990 rs4938933 11342 1 chr11:59791005 
rs4938933 rs7108663 6287 1 chr11:59784718 
rs4938933 rs4938931 7816 1 chr11:59783189 
rs4938933 rs1562990 11342 1 chr11:59779663 
rs744373 rs730482 131 1 chr2:127610954 
rs157580 No proxies 
rs610932 No proxies 
 
one proxy, rs730482. The remaining two SNPs, rs157580 and rs610932 had no proxies 
in r2=1 in the 1000 Genomes database.  
 
Between rs4938933/rs1562990 and rs610932, r2 = 0.66. Although the graphical 
representations of the three SNPs’ effects on gene expression looks very similar (see 
figure 6.1.b-d) and they have similar effect sizes on MS4A6A, the two intergenic SNPs 
are not in high linkage disequilibrium with 3’ UTR SNP rs610932. 
 
6.6 Expression associations with cognitive decline 
6.6.1 Probe selection  
In November 2010, when PCR plates were designed and run, the publications citing 
SNPs near MS4A6A associated with Alzheimer disease (Naj et al., 2011, Hollingworth et 
al., 2011, Antunez et al., 2011) had not yet been published. qRT-PCR quantification was 
therefore carried out using probes for BIN1 and PVRL2 only. The assays used were 
selected from the Applied Biosystems TaqMan® Gene Expression Assays inventory: 
Hs00184913_m1 (amplicon length 69) for BIN1 and  Hs01071562_m1 (amplicon length 
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Table 6.4 Mean Ct for genes amplified by qRT-PCR. The mean threshold cycle across 
all samples is presented (Ct), ordered by standard deviation (SD) of mean Ct  
 
Gene 
Mean Ct across  
all samples 
SD 
PPIA 22.893 0.878 
GAPDH 22.474 1.002 
BIN1 25.258 1.080 
PVRL2 28.473 1.759 
 
61) for PVRL2. Both probes bind to exon-exon boundaries spliced into all RefSeq 
annotated transcripts known to be produced from each gene (including all of BIN1’s 10 
annotated transcripts). 
 
6.6.2 Participant selection 
Using a 13-predictor multiple logistic regression model to analyse the results of the RT-
PCR experiment, this phase of the study required sample sizes of 48 to have power of 
0.8 to detect an anticipated effect size of 0.5 between case and control groups. 50 
control and 50 case participants were therefore selected according to the algorithm 
detailed in setion 2.9.7. 
 
6.6.3 RT-PCR target genes and control 
RT-PCR, conducted using a Tiled Low Density Array (Applied Biosystems), quantified 
expression of genes BIN1, PVRL2, GAPDH and PPIA. Genes BIN1 and PVRL2 were 
included for quantification as part of this project; GAPDH and PPIA were included as 
endogenous housekeeping genes. Raw expression results from the RT-PCR 
experiments are shown in the table below (ordered by standard deviation), presented 
as mean fluorescence threshold crossing points (Ct) across all samples and technical 
replicates for each of the 4 genes.  
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Table 6.5 Relative quantification of BIN1 and PVRL2 expression by cognitive 
phenotype. The mean relative quantification (RQ) of BIN1 and PVRL2 (derived by the 
formula 2-ΔΔCt) is given, grouped by cognitive phenotype (cognitive maintenance or 
cognitive decline). Also given are the numbers of samples (N) eligible for expression 
analysis of BIN1 and PVRL2 after outlier exclusion, and the standard deviation (SD) of 
mean RQ for each group 
 
Phenotype 
BIN1 PVRL2 
N  Mean RQ SD N  Mean RQ SD 
Cognitive maintenance 49 1.051 0.336 46 1.183 1.424 
Cognitive decline 44 0.932 0.392 40 1.324 1.820 
 
6.6.4 Relative quantification of BIN1 and PVRL2 
After RT-PCR completion for all samples, the comparative (Ct) method was used to 
quantify expression of BIN1 and PVRL2 relative to the mean expression level of control 
genes (calibration by gene) and then relative to the mean expression of all samples in 
the control group (calibration by sample). This produced a relative quantification for 
BIN1 and PVRL2 in each sample (table 6.5, figure 6.2).  
6.6.5 RT-PCR analysis 
The association between gene expression (defined by RQ value) and cognitive decline 
was tested using a multivariate logistic regression model adjusted for age, sex, highest 
level of education received, site of blood collection, pack years smoked, and 
percentage of different lymphocyte percentages present in blood samples as fully 
described in section 2.9.11. After these adjustments, expression of neither gene had a 
statistically significant association with cognitive decline (BIN1 odds ratio for cognitive 
impairment 0.110, p=0.096. PVRL2 odds ratio for cognitive impairment 1.26, p=0.422). 
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Figure 6.2.a 
 
 
Figure 6.2.b 
 
Figure 6.2 Relative quantification of expression in control and case groups. The 
boxplots show the spread of relative quantification of gene expression (relative units) 
as plotted on the y-axis by phenotype (control = cognitive maintenance, case = 
cognitive decline) on the x-axis. Boxes represent the 25th to 75th percentiles of relative 
expression, central bars represent median relative expression, and whiskers represent 
the 5th and 95th percentiles of relative expression. Dots represent outlying values. 
Figure 6.2.a shows the spread of relative quantification values for BIN1 expression in 
control and case groups; figure 6.2.b shows the spread of RQ values for PVRL2 
expression in control and case groups. Relative quantification of the expression of 
neither gene had a significant association with phenotype 
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Chapter 7 Discussion 
 
7.1 Main findings 
The aim of this study was to assess associations between cognitive performance, cognitive 
decline and peripheral leukocyte gene expression. In doing so, the hope was that this study 
would advance the understanding of the association between blood leukocyte-based 
gene expression and cognitive decline, and the mechanisms behind significant 
associations.  
 
The main findings were that in this population cohort: 
1) Peripheral leukocyte expression of one gene, CCR2, was significantly associated 
with cognitive performance at date of RNA collection 
2) No peripheral leukocyte genes’ expression had a significant association with 
cognitive decline over the preceding 9 years 
3) Inflammatory subset expression analysis identified an association between 
CCR2 and cognitive decline, but no further peripheral inflammatory 
associations with cognitive decline 
4) Four genetic variants for AD were associated with expression of three genes, 
BIN1, MS4A6A and PVRL2, but expression of these genes did not have a 
significant association with cognitive decline  
 
This study has examined the role of peripheral gene expression in association with 
cognitive decline in a population-based cohort. The study has taken two approaches. 
First, it used genome-wide expression data to identify peripherally expressed genes 
and gene pathways associated with cognitive decline. Second, it used available 
evidence from recent genome-wide association studies to perform a focused 
candidate-driven investigation of genetics and gene expression in cognitive decline. In 
doing so, this study made use of three analytical tools crucial to the investigation of 
complex traits: starting from the investigation of large expression effects on 
phenotype, it narrowed to investigate moderate expression effects combined across 
pathways, and finally focussed in further onto small expression effects associated with 
100 
known genetic risk factors for disease. Previous studies have successfully used this 
combined approach to investigate non-candidate associations with complex traits 
(Wheeler et al., 2009, Cookson et al., 2009) (fig. 7.1). 
 
 
 
 
 Figure 7.1 A multifaceted approach to the analysis of complex traits. Taken from 
Cookson et al. (2009), this study’s chosen facets of investigation (gene expression, 
genotyping, eQTLs and integration with genome-wide association studies) are seen to 
form key parts of the multifaceted analytical approached needed in the investigation 
of any complex trait 
 
 
The investigations pursued in this study have not found peripheral inflammatory gene 
expression abundance to have a significant association with cognitive performance or 
cognitive decline in this cohort.  
 
101 
The unique extension of knowledge provided by this study lies in its presentation and 
analysis of 1) the first genome-wide expression study of cognitive decline in a large 
cross-sectional population-based cohort and 2) a novel functional link between 
genome and transcriptome for known risk SNPs for a cognitive decline trait. 
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7.2 The cognitive decline phenotype 
This study used the MMSE as its only measure of cognitive performance. Studies 
investigating the sensitivity and specificity of cognitive impairment screening tools 
have found that short tests with easy scoring systems tend to be more accurate than 
longer tests with more complex scoring systems (Fillenbaum et al., 1990), which makes 
the MMSE an ideal measurement tool for cognitive impairment in a large population 
not drawn from specialist clinics. Other studies have made use of more specific 
neuropsychological tests in their observational studies of cognitive decline e.g. the 
Framingham cohort study of Alzheimer’s disease (n=1076) undertook Wechsler 
memory scale, Wechsler adult intelligence scale and multilingual aphasia examinations 
(Elias et al., 2000). However, Amieva et al used the global MMSE alongside more 
specialised neuropsychological measures including the Benton visual retention test, 
Isaacs set test and Wechsler similarities tests to assess cognitive decline in the PAQUID 
cohort (study n=1265), and found the MMSE to reflect cognitive decline suitably in 
their cohort (Amieva et al., 2005).  
 
In this cohort, MMSE score decline has provided a representative phenotype of 
cognitive decline. Cognitive decline defined by MMSE score change had a statistically 
significant association with age, sex and education in this cohort (see section 3.3). 
These associations concur with the findings from other large population-based cohort 
studies of cognitive decline (Letenneur et al., 1999, Cullum et al., 2000, Amieva et al., 
2005, Daviglus et al., 2010) including the PAQUID study, whose cohort was drawn from 
a similar ethnic background to the InCHIANTI population (Letenneur et al., 1999). The 
model used in this study can therefore be taken as a reliable representation of 
cognitive decline phenotype in this population.  
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7.3 Few positive findings from a well-powered genome-wide 
expression study 
The genome-wide phases of this study involved analysis of 16,571 expression probes in 
691 individuals using a multiple regression model adjusted for relevant potential 
confounding factors. The analysis had power to detect significant moderate-to-large 
differences in mean gene expression (>0.25 SD). The study identified one gene, CCR2, 
associated with cognitive performance but identified no genes whose expression had a 
significant association with cognitive decline. Further, inflammatory gene subset 
analysis had greater power to detect expression associations with cognitive decline but 
again identified only a single gene (CCR2) significantly associated with cognitive 
performance and cognitive decline. The discovery that only one peripheral leukocyte 
genes’ expression had a significant association with cognitive performance and 
cognitive decline was an unexpected result from such a well powered study, given 
other groups’ prior proteomic, genomic and expression findings, as outlined in section 
1.3.4.3. 
 
As the largest study of the field to date, this work presented a preliminary analysis of 
the available data with the aim of producing candidates for further investigation. The 
largely negative results add significant knowledge to a field which has largely been 
informed by smaller, case-control studies of pathologically defined phenotypes. The 
implications for future work and the place of these negative findings in the field of 
cognitive decline research are presented in detail in section 7.10.  
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7.4 Inflammatory gene chemokine receptor (C-C motif) receptor 
2 (CCR2) associates with cognitive performance, and with 
cognitive decline in a subset analysis 
The genome-wide phase of this study analysed cognitive performance at the date of 
RNA extraction for association with gene expression. One gene, CCR2, tagged by probe 
ilmn_1774761, was found to have a significant association with MMSE score 
(coefficient -0.004, p= 5.09x10-6, qval= 0.08). CCR2 also had a significant association 
with cognitive decline (coefficient -0.004, p= 5.49x10-5, q= 0.0333) when a subset of 
inflammatory-related genes was analysed.  
 
CCR2 encodes a monocyte chemoattractant receptor expressed both by microglia and 
by monocytes, and mediates monocyte chemotaxis to sites of inflammatory stimuli. Its 
ligand, chemokine (C-C motif) ligand 2 (CCL2), is abundantly expressed in microglia and 
in vascular atherosclerotic plaques (El Khoury et al., 2007).  
 
Current evidence suggests a role for CCR2 and CCL2 in the vascular and protein 
deposition pathways of cognitive decline pathogenesis (Yamamoto et al., 2005, El 
Khoury et al., 2007, Naert and Rivest, 2011). In a mouse model of experimental 
autoimmune encephalomyelitis, Izikson et al demonstrated that neuroinflammation 
triggers Ccr2-mediated systemic monocyte migration and infiltration into the brain 
(Izikson et al., 2000). Mildner et al investigated myeloid cell recruitment to β-amyloid 
plaques in mice and found CCR2-expressing cells to be the preferentially recruited 
subset (Mildner et al., 2011). Assessing both pathological and functional changes, El 
Khoury et al. found Ccr2 deficiency to be associated with reduced microglial 
accumulation and early disease progression in a mouse model of AD (El Khoury et al., 
2007). Naert and Rivest used triple transgenic CCR2 knockout mice expressing 
mouse/human β-amyloid precursor protein and human presenilin I to demonstrate 
that CCR2 deficiency is associated with increased amyloid deposition, worsened 
cognitive defects and accelerated disease onset in an AD model. They suggest that 
decreased CCR2 could play a role in the aetiology of Alzheimer’s disease by inhibiting 
inflammation-mediated Aβ degradation triggered by the presence of Aβ plaques 
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(Naert and Rivest, 2011). In their functional analysis, Villeda et al. (2011) demonstrated 
that, in mice, levels of peripheral Ccr2 increased with ageing and correlated with 
reduced neurogenesis during ageing (Villeda et al., 2011). 
 
In the systemic circulation, chronic inflammation is a key early aetiological factor in the 
development of atherosclerotic plaques (Mestas and Ley, 2008). Circulating monocytes 
adhere to and accumulate in the subendothelium of damaged arterial walls early in 
atherosclerotic plaque formation (Mestas and Ley, 2008). In ApoE-deficient mice which 
develop spontaneous hypercholesterolaemia (making them markedly susceptible to 
atherosclerotic plaque formation) CCR2 downregulation is associated with reduced 
atherogenesis (Dawson et al., 1999), possibly as a result of CCR2 depletion decreasing 
monocyte chemoattraction to plaque formation sites. A reduction of monocyte 
adhesion could reduce incipient plaque development, suggesting a causal association 
between CCR2 expression and pathology progression. In this situation, therefore, CCR2 
could be postulated as a causative factor in disease progression, as opposed to its 
putatively reactive role in the clearance of neural plaques. 
 
In the current study, increased CCR2 is associated with poor cognitive performance, as 
in the animal models of cognitive decline described above. One theory could therefore 
be that reduced CCR2 levels act to reduce peripheral vascular inflammation, leading to 
or reflecting reduced neuroinflammation in cognitively healthy individuals. However, 
the marked absence of multiple other peripheral inflammatory factors in the genome-
wide data suggests that the association between CCR2 expression and cognitive 
performance is more likely to be reactive rather than causal. Considering the evidence 
generated by this study, one possibility is that a reactive downregulation of CCR2 is 
identified in peripheral leukocytes in response to the reduced β-amyloid load of 
cognitively healthy individuals.  
 
Notably, results of the current study are in concordance with functional data from 
Naert and Rivest’s CCR2-knockout mouse model (Naert and Rivest, 2011). One 
potential application could therefore be an increased confidence in the CCR2-knockout 
mouse as a relevant and representative tool in the study of human AD and cognitive 
decline. The mouse model is an ubiquitous knockout with all the compensatory and 
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additional physiological features (including haematopoetic disregulation) that this 
brings, making it, as with all animal models, very different to the human model of 
cognitive impairment (Rivera and Tessarollo, 2008). Despite this discrepancy, the 
functional changes mirrored by this study and the mouse model go some way towards 
increasing the hope of a mouse model useful in the study of human cognitive decline. 
 
7.4.1 CCR2 probes tag different isoforms  
In both genome-wide and inflammatory subset analyses, ilmn_2276996, a second 
probe for CCR2, had a statistically insignificant association with cognitive performance 
and decline. To date, CCR2 has 2 known representative transcript isoforms and an 
additional spliced variant. The known mRNA sequences of these transcripts (taken 
from the NCBI AceView website 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html) (Thierry-Mieg and 
Thierry-Mieg, 2006), were therefore analysed against the 50-mer RNA sequences of 
each CCR2 probe (from the Illumina annotation file), to identify which Illumina probes 
quantified expression of each transcript. The significantly assocseiated probe for CCR2, 
ilmn_1774761, picks up expression of both CCR2 isoforms .a and .b, while the 
insignificantly associated probe, ilmn_2276996, picks up expression only of isoform .a.   
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7.5 Concordance with other studies of gene expression in 
cognitive decline 
Previous case-control and longitudinal studies in peripheral blood have presented 
evidence (described in section 1.3.5) for leukocyte cytokine and gene expression 
associations with dementia and cognitive decline.  
 
The findings of Dik et al. (2005), while positive, are not directly comparable to the 
findings of this study. Dik et al. analysed serum proteomics and identified an odds ratio 
of 1.6 for serum levels of protein α1-antichymotrypsin in association with MMSE score 
decline in a large longitudinal study (n=1,284) (Dik et al., 2005). Gene ACT, coding for 
α1-antichymotrypsin, is not expressed by peripheral lymphocytes and was therefore 
not quantified as part of this investigation. However, several other leukocyte-
expressed genes and proteins have been found previously to have significant 
associations with cognitive decline (Giunta et al., 2007, Maes et al., 2007, Bonotis et 
al., 2008; Grunblatt et al., 2009). 
 
Discrepancies between the data presented by this study and previous positive findings 
(Maes et al., 2007, Grunblatt et al., 2009) could be the result of various factors. First, 
the mismatch could arise as a result of different patient selection criteria: this study 
used population data while previous smaller studies made use of careful case-control 
participant selection from clinical settings. Second, prior proteomic findings of 
peripheral blood biomarkers of cognitive decline (Dik et al., 2005, Ray et al., 2007) may 
conflict with these transcriptomic findings as a result of significant post-translational 
protein modification in leukocytes; variance between a gene’s expression abundance 
and quantity of its relevant protein is often large (Tyers and Mann, 2003). A third 
possibility is that the circulating cytokines previously found associated with cognitive 
decline may be expressed by activated CNS inflammatory cells and released into the 
circulation, rather than being expressed by circulating leukocytes (Licastro et al., 2000). 
Discrepancies between this and previous studies were therefore unsurprising. What 
was striking was an almost complete lack of any significant associations, be they 
validations of others’ findings or novel associations with phenotype. One possibility for 
this finding was that the genome-wide study, powered to detect moderate or large 
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associations, simply missed small expression effects having a cumulatively significant 
effect on phenotype as detected by other groups. The clinical implications of small 
individual expression effects on phenotype remain unclear, but these small effects 
could have reached significance in smaller, candidate-driven investigations and missed 
the threshold in this large, multiple hypothesis corrected analysis. One benefit, 
therefore, of this study’s subsequent gene set enrichment analysis was that it added a 
further line of evidence to support the hypothesis that these were true negative 
results, rather than the results of a study under-powered to detect significant effects 
contributing to phenotype. 
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7.6 Gene set enrichment analysis 
In large-scale gene expression studies, modest expression effects associated with 
phenotype do not pass stringent significance thresholds when subject to multiple 
hypothesis testing corrections (Subramanian et al., 2005).  This study therefore 
progressed from genome-wide analysis to investigate functional groups of genes 
associated with cognitive decline. Unifying thousands of individual genes into their 
relevant biological pathways and analysing pathways’ association with phenotype 
increased the study’s power to detect significant but modest associations.  
 
Regulation of cell activity and behaviour is not controlled by single genes or genetic 
changes acting in isolation. Rather, function is determined by highly complex 
interactive transcriptomic and molecular networks under constant homeostatic 
control. Genes that function in a similar biological pathway may demonstrate co-
ordinated expression changes to respond to a particular change to their environment. 
This means that expression throughout functional sets of genes, when measured as a 
unit, may correlate with phenotype when the pathway genes themselves do not 
individually meet significance thresholds: the small insignificant changes in the 
pathway genes combine to produce a united significant association with phenotype.  
 
Gene pathway analysis therefore added an important second line of evidence to this 
study which had previously considered individual genes in isolation. In complex traits 
where multiple factors influence cellular phenotype, let alone phenotype of the entire 
organism, the consideration of gene groups acting in concert increases the scope of 
the evidence added by this study to the field of cognitive decline research. The 
identification of a defined group of pathway-related genes, each with small effect 
sizes, associated with cognitive decline could provide a clinically useful molecular 
signature for the detection and monitoring of cognitive change, and would provide 
insight into the processes and networks by which a particular phenotype is generated. 
 
The gene set enrichment analysis conducted was more highly powered than the 
preceding transcriptome-wide analysis to detect small-to-moderate expression effects 
for two reasons. Testing cognitive phenotype association with 848 gene pathways 
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compared to 16,571 probes increased power by 1) combining the small effect sizes of 
multiple genes into a single pathway effect size, and 2) reducing the magnitude of 
necessary multiple testing adjustments. Despite this increased power to identify 
significant and contributory small expression effects, gene set enrichment analysis did 
not detect gene pathways or groups associated with cognitive decline. Even CCR2’s 
significant stand-alone association with cognitive performance was attenuated when 
analysed alongside the insignificant expression effects of the other genes in its 
associated pathways. If other inflammatory pathway genes had a small but similarly 
negative association with cognitive performance, these pathways would have reached 
significance at GSEA. The pathway attenuation of CCR2’s association therefore served 
to strengthen the conclusion that, within the power limitations of this study, 
peripheral inflammatory gene expression abundance plays an insignificant role in the 
development or reflection of the pathology of cognitive decline in this cohort. 
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7.7 eQTL analysis 
The eQTL phase of this study was a hypothesis-driven investigation into significant 
genetic variants associated with AD, a prevalent contributor to cognitive decline in the 
population. This approach focused on candidate genetic variants in order to further 
the understanding of the links between genetics and functional phenotype in cognitive 
decline. The SNPs investigated are known to have a significant association with AD; it is 
their mechanism of action that remains to be investigated.  By investigating gene 
expression, the sub-phenotype most closely connected to genetic variance in the 
cascade of effects from genome to phenotype, this study investigated the first step in 
the process linking genetic variation to heterogeneous phenotypic presentation. 
 
eQTL mapping has, since 2001, revealed significant heritable variation in gene 
expression within populations (Gilad et al., 2008). Individual eQTLs rarely contribute 
more than 20% to genetic variance in any given clinical phenotype: instead, variation in 
visible trait is often described by several cumulative eQTLs, which can together 
contribute up to half of the genetic variance in phenotype (Gibson and Weir, 2005). 
Individual eQTLs do, however, contribute significantly to variance in the transcriptomic 
phenotype, that is, at the level of the mRNA. eQTLs have been found to account for 25-
50% of transcriptional variation in a range of quantitative transcription studies (Gibson 
and Weir, 2005). It is postulated that multiple eQTLs with a cumulatively large effect 
size could be key drivers in complex traits such as AD (Schadt et al., 2005).  
 
A genetic change significantly associated with both expression of a gene and with 
clinical phenotype suggests the possibility of an association (of indeterminate 
direction) between gene expression and phenotype. This study has not identified any 
significant link between expression and phenotype, but it has contributed an improved 
understanding of how risk SNPs impact on gene expression. This advances the 
understanding of 1) the mechanisms by which risk SNPs for AD act, and 2) the 
molecular pathways on which to focus in investigating known genetic determinants of 
AD.  
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7.7.1 SNPs are significant for AD, not for cognitive decline 
To date, no SNP has been identified as having a genome-wide significant association 
with cognitive decline. SNPs associated with late-onset AD (the major pathological 
contributor to cognitive decline in the community) have, however, been found to be 
significant at GWAS  (Harold et al., 2009, Lambert et al., 2009, Seshadri et al., 2010, 
Feulner et al., 2009, Hollingworth et al., 2011, Naj et al., 2011, Antunez et al., 2011). 
For these SNPs, mechanisms of action remain unknown. This study therefore 
investigated SNPs associated with AD using an eQTL analysis to understand whether 
they acted as quantitative regulators of gene expression. 
 
It is likely that risk SNPs have been identified for AD and not for cognitive decline 
because participant selection for AD studies involves a clinical phenotype dependent 
on specific biological changes, rather than a heterogeneous functional phenotype. 
Significant genetic changes affecting functional phenotype by other pathways are 
ignored, and the signal-to-noise ratio between individual genetic changes and 
case/control phenotype is improved when considering the biological phenotype of AD 
compared to the functional phenotype of cognitive decline. Significantly, however, 
clinical selection for the AD GWA studies used in SNP identification for this paper 
included the necessary demonstration of cognitive decline. It is well established that 
AD pathology does not always correlate with clinical phenotype, but individuals who 
exhibit pathology without cognitive decline were excluded from the GWA studies. 
Genetic variants found to affect AD in these studies therefore contribute to cognitive 
change and are eligible for investigation in studies of cognitive decline. 
 
AD accounts for at least 56% of dementia cases in the UK (Luengo-Fernandez et al., 
2010). The characterisation of SNPs contributing to AD therefore allowed this study to 
investigate causative variants for a crucial pathological contributor to cognitive 
decline. However, the limitations of this study phase (driven by genetic associations 
with only a sub-phenotype of cognitive decline) are that the selected genetic variants 
may exert specific phenotypic effects in only a subset of specialized patients, 
weakening their association with phenotype across the cohort. In addition, the effect 
sizes of these variants will vary among individuals in whom pathological pathways play 
different proportional roles (see section 1.2.2). However, with no SNPs yet identified 
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for cognitive decline or for other biological phenotypes of the trait, the investigation of 
risk SNPs for AD was a useful place to start in understanding the associations between 
genetic variation and cognitive decline.  
 
7.7.2 Are the identified genes sensible candidates for cognitive decline? 
A key feature in the analysis and discussion of eQTL results is that associations 
between genetic variance and other features e.g. gene expression or functional 
phenotype must be causative; inherited genetic changes are present from conception, 
preceding any other observed changes. The purpose of this eQTL study was to take 
known causative genetic risk factors for Alzheimer’s disease and to contribute insight 
into how they were exerting their effect. The result has been the identification of two 
genes which are significantly affected by these genotype variations. The genes 
themselves, BIN1 and MS4A6A encode a bridging integrator and a member of the 
membrane-spanning 4-domain gene family respectively. While neither has a significant 
association with the phenotype of cognitive decline in this cohort of individuals, do the 
genes’ known attributes provide any information about the pathways through which 
genetic variants could be acting to cause phenotypic change in Alzheimer’s disease? 
 
7.7.2.1 BIN1 
The significant association between rs744373 and AD has been substantially verified, 
but functional studies have yet to investigate BIN1’s role in the aetiology or pathology 
of AD. The results of this study present evidence that rs744373 and BIN1 may be 
functionally linked.  
 
Gene BIN1 encodes isoforms of a nucleocytoplasmic adaptor protein. Bin1 has at least 
10 different isoforms produced by alternative transcript splicing, and these isoforms 
are differently expressed across different tissues (Wechsler-Reya et al., 1997). In 
muscle, Bin1 interacts with Dnm2 to promote normal function, possibly through 
endocytic membrane remodelling (Nicot et al., 2007). In the central nervous system, 
Bin1 is suggested to act as a clathrin adaptor protein, mediating synaptic endocytosis 
(Yao et al., 2010). Global loss of synaptic integrative function is a key feature of 
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cognitive decline in older adults; changes to synaptic endocytic proteins including BIN1 
could possibly contribute to this loss of function. The gene therefore has fair candidacy 
for involvement in cognitive decline.  
 
7.7.2.2.MS4A6A 
This gene has not yet been characterized to the same extent as BIN1; its in vivo 
functions remain, to date, unknown. MS4A6A is part of a gene superfamily, with all 
genes in the MS4A family sharing 25-40% amino acid identity (Ishibashi et al., 2001). 
Genes in this family code for membrane-spanning proteins thought to have a role in 
multimeric receptor signal transduction (Ishibashi et al., 2001). Family gene MS4A1 
promotes B-cell differentiation into plasma cells, while MS4A2 encodes the beta 
subunit of a high-affinity receptor for the Fc portion of IgE and is involved in 
lymphokine secretion (data taken from the NCBI Reference Sequence database (Pruitt 
et al., 2005)). Neither of these genes is known to be expressed in brain. Structurally, 
MS4A6A’s protein, M4A6A, has similarity to CD20, a Ca2+-permeable cation channel 
(Ishibashi et al., 2001).  
 
From the available information, it is not possible to suggest a role for MS4A6A in 
cognitive decline pathology, although a role in the immune system seems most likely 
given the function of other genes in its family. Future work on the gene and its protein 
will provide the necessary functional information, and may identify MS4A6A as coding 
for a calcium channel.  
 
7.7.3 eQTLs are probably cis-acting 
eQTLs are broadly divided into two categories: cis-eQTLs and trans-eQTLs. Cis-eQTLs 
have an allele-specific effect on gene expression, e.g. affecting promoter or splice site 
selection elements while trans-eQTLs affect both alleles, e.g. altering transcription 
factors or regulating siRNA. These categories make for two generalisations about eQTL 
function. First, cis-eQTLs will most probably only affect expression of one gene, while 
trans-eQTLs may affect expression of multiple genes through the same mechanism. 
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Second, cis-eQTLs will probably be located local to their target gene (typically within 
100kb), while trans-eQTLs are, in general, located more distantly (Gilad et al., 2008).  
 
The implication for this study is therefore that the identified SNPs, being located in or 
proximal to their target genes, are probably cis-eQTLs and will exert allele-specific 
effects on gene expression. The transcriptome-wide search for genes affected by risk 
SNPs revealed no trans-eQTL activity (e.g. no SNPs affected multiple or distant genes), 
but authors have previously reported that distant eQTLs exert much smaller effect 
sizes over individual genes’ expression than local eQTLs (Dixon et al., 2007). This 
knowledge makes it important to note that investigated eQTLs could possibly be acting 
in trans, and that only the strong, local (putatively cis-) eQTLs were identified by this 
study.  
 
7.7.4 Putative eQTL effects on genes 
One eQTL identified by probe association analysis (rs610932 for MS4A6A) lies the 3’ 
UTR of the gene it targets. Three other eQTLs – one for BIN1 and two for MS4A6A - are 
intergenic and lie upstream of the genes with whose expression level they associate. 
PVRL2’s eQTL lies downstream, in the intron of a separate gene. 
 
eQTL location relative to gene can give clues as to eQTLs’ potential function. For 
MS4A6A, the effect sizes of the three eQTLs are all very similar. It is therefore possible 
that they could be tracking the same functional variant, as suggested by Antunez et al. 
(2011). Genome-wide association studies identify areas of the genome that are 
significantly associated with trait. Accordingly, validation studies occasionally identify 
neighbouring, but not identical, regions of DNA as GWA-significant for the same trait. 
For these novel findings near MS4A6A (April 2011), it is possible that as validation 
studies for the region are conducted, the area of interest associated with trait will be 
narrowed down and the functional SNP identified.  
 
Functional eQTLs are commonly located both in exons and in the regulatory elements 
of the genes they affect (Veyrieras et al., 2008). If the SNP in the 3’ UTR of MS4A6A 
was the functional variant, it could be exerting regulatory influence by altering a 
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microRNA target: microRNAs suppress expression of mRNA by binding to the 3’UTR 
and targeting mRNA either for degradation or translation inhibition (Thomas et al., 
2010). The eQTL could alternatively act by causing variation in the secondary structure 
of the RNA and therefore altering its stability. rs610932 is only present in two of the 
three annotated isoforms of MS4A6A and, if functional, would therefore have an 
isoform-specific effect on expression. Working with Dr. Harries, the TargetScan web 
server (release 5.2) (www.targetscan.org/) (Lewis et al., 2003) was used to search for 
miRNA seed regions in the 3’UTR of MS4A6A. This revealed no annotated miRNA 
targets containing rs610932, making rs610932 unlikely to act through altering miRNA 
regulation. MS4A6A’s RNA sequence was then run through the MFold web server 
(http://mfold.rna.albany.edu) (Zuker, 2003) to search for predicted RNA 2o structure 
based on sequence. rs610932 causes an A to C switch; both versions of the sequence 
were therefore inputted, and their predicted RNA 2o structures identified by the 
server. Both versions of the sequence form stabilising base pairs at rs610932, but the 
two versions of the sequence have different 2o structure. It is therefore possible that 
the SNP, if functional, affects mRNA stability and therefore translation and gene 
expression (Duan et al., 2002).  
 
Mechanisms by which the 5’ intergenic eQTLs for MS4A6A could directly regulate gene 
expression include alteration of a transcription factor binding site, alteration of 
enhancer or boundary elements, disruption of antisense expression, or miRNA 
expression disruption. Genes’ regulatory elements have been found located in the 
introns of entirely separate genes (Eisberg et al., 2008), and this could be the case for 
rs157580, regulating PVRL2 but located in TOMM40. However, cis-eQTLs will typically 
be located no more than 20kb distant of the gene they affect (recent work estimates 
95% of eQTLs lie within this range of their gene), and eQTLs are observed most 
abundantly in the 250bp region immediately upstream of their associated gene’s 
transcription start site (Veyrieras et al., 2008). This, and the knowledge that the 
intergenic eQTLs for MS4A6A lie in a block of high linkage disequilibrium, suggest a 
further potential mechanism of action for these SNPs, namely, regulation of a 
mediator gene. 
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7.7.5 Mediator genes 
Two eQTLs and proxies for MS4A6A lie in an intron of a putative gene, HQ447086. 
Similarly, the eQTL for PVRL2 lies in the intron of a known gene, TOMM40. eQTLs could 
therefore be exerting a trans-eQTL influence over target gene expression through 
altered levels of HQ447086/TOMM40  RNA or protein. The expression intensities of 
TOMM40 and PVRL2 do not have a statistically significant association when assessed 
using a multiple linear regression model adjusted for potential confounding factors 
(coefficient -0.18, p=0.063), nor does TOMM40 have a statistically significant 
association with genotype at rs157580 (p=0.729). These initial investigations suggest 
that the effect of rs157580 on PVRL2 is not mediated by TOMM40. Considering eQTLs 
for MS4A6A, QC-passed microarray results do not contain probe expression data for 
putative gene HQ447086. Accordingly, this study is unable to investigate whether 
significant SNPs are eQTLs for HQ447086 and having a downstream trans-eQTL effect 
on MS4A6A expression. Functional investigation of the possible association between 
eQTLs and genes HQ447086 and TOMM40 would aid the understanding of whether 
these genes are acting as mediators, and would also help to distinguish MS4A6A’s true 
functional eQTL from among the candidates. Future work would involve quantitative 
PCR of HQ447086 to establish whether eQTLs are affecting expression of both genes, 
or independently affecting gene MS4A6A, suggesting a different functional variant for 
MS4A6A. 
 
7.7.6 Power of RT-PCR analysis  
Previous studies investigating the association between eQTL-affected gene expression 
and clinical phenotype have often produced negative results. This is because the 
phenotype-associated eQTL often has a small effect on gene expression. With many 
additional factors impacting on phenotype, the expression effect on phenotype is lost 
in a large field of interacting elements, even if a significant association exists (Moffatt 
et al., 2007).  
 
The aim of the RT-PCR experiment was to investigate associations between gene 
expression and clinical phenotype using a gold-standard method of expression 
analysis. This phase of the study was designed to have 0.8 power to detect an gene 
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expression effect size of 0.4 between two groups of 50 samples using a logistic 
regression model with 11 covariates, as detailed in section 2.9.11. A trending 
association was seen between lower BIN1 expression and phenotype, but the RT-PCR 
analysis was most likely underpowered to detect any true association between gene 
expression and phenotype.  
 
Considering RT-PCR validation of the genotype-expression link identified using the 
microarray, RT-PCR expression data was available for only 78 individuals for whom 
rs744373 had been genotyped, and only 2 of these individuals had both copies of the 
minor allele at rs744373. Similarly, PVRL2 RQ expression data were available for only 
71 genotyped individuals, 6 of whom had both copies of the minor allele. The 
experiment therefore did not have sufficient power to validate eQTL effect on gene 
expression as identified by the initial microarray study. eQTL validation was not the 
primary aim of the RT-PCR step and therefore its absence does not detract from 
analysis of the results. However, this group has access to RNA samples from over 90 
individuals who contain both copies of the minor allele at each eQTL. If the experiment 
were to be repeated, a larger cohort with more balanced numbers of individuals from 
each genotype group could be included for analysis; this would serve to increase the 
power of both genotype-expression analysis and expression-phenotype analysis. 
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7.8 Study strengths 
7.8.1 Large population-based longitudinal study of gene expression 
Longitudinal population-based studies of cognitive decline in older people have 
provided key insights into population prevalence and incidence of MCI and dementia 
(Anstey et al., 2008a, Cullum et al., 2000) and the cognitive changes occurring in 
preclinical dementia and AD patients (Amieva et al., 2005, Elias et al., 2000). These 
studies made use of the MMSE and additional neuropsychological tests in their data 
analysis to examine sociodemographic and diagnostic variables, but most did not 
investigate biological markers associated with performance change. The PATH Through 
Life cohort (n=2,222) underwent DNA extraction from cheek swabs alongside basic 
physiological function tests, but this information was not incorporated into the 
authors’ longitudinal investigation of MCI (Anstey et al., 2008a). The InCHIANTI study 
therefore presents a uniquely large population-based cohort of older adults in which 
to assess peripheral gene expression associations with cognitive decline. This large 
population-based study is the first in the field to incorporate gene expression, genomic 
and cognitive data to provide a picture of the interaction between these domains in 
cognitive decline.  
 
The 9 year follow-up period undertaken in this cohort presents the first insight into 
peripheral expression associations with long-term cognitive decline in the population. 
In addition, the continued follow-up of participants beyond this study presents an 
opportunity for prospective association studies between genomic, transcriptomic and 
phenotypic traits in the same cohort. 
  
7.8.2 Functional phenotype 
For this study, participants’ cognitive decline has been examined regardless of its 
pathological subtype(s) with the aim of identifying markers of cognitive decline in a 
population-based cohort. The functional, rather than pathological, classification of 
cognitive decline was important for three reasons. Firstly, the functional impairment 
resulting from cognitive decline is a major public health threat regardless of pathology 
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(Njegovan et al., 2001). Secondly, cognitive decline is rarely determined purely by one 
pathophysiological mechanism (Wilson et al., 2010); indeed, functional decline has 
only a moderate association with the pathological changes of Alzheimer’s disease 
(Daviglus et al., 2010). Thirdly, analysis of a large cohort of participants selected from 
the population, rather than from specialist clinics, gave this study power to detect 
moderate biomarker effects that would be of clinical application in population testing 
and risk reduction: biomarkers of functional cognitive change will hold more clinical 
application in the population than markers of single pathological processes.  
 
The study therefore presents a significant step in the understanding of peripheral gene 
expression in functional cognitive decline, building on the basis of smaller, 
pathologically-defined case and control studies, and indicating the limitations of 
peripheral gene expression analysis in the investigation of cognitive decline in the 
population. 
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7.9 Study limitations 
7.9.1 Drawbacks of a functional phenotype 
The use of a functional phenotype also presents major limitations in interpreting and 
drawing implications from studies such as this one. The signal-to-noise ratio between 
genetic variance and transcriptomic change is high, allowing small genetic effects to be 
identified in an endo-phenotype dependent on genetics and few other factors 
(Montgomery et al., 2010). However, from transcriptome to functional phenotype, a 
huge number of additional and interacting influences come into collaborative play. 
Although investigation of social, physical and environmental influences on cognitive 
decline have thus far revealed few modifiable or validated risk factors for cognitive 
decline development, it remains true that changes to the transcriptome will be 
influenced by changes at the level of the proteome, the cell, and (further removed 
from gene expression) at the level of the biological system and the entire organism. 
Studies of individual pathological processes do, therefore, add a great deal of 
knowledge to the investigation of multifactorial diseases, as they allow the dissection 
of phenotype into definable and measurable endo-phenotypes. The signal-to-noise 
ratio is improved when stepping back from functional to pathological phenotype. It is 
for this reason that this study may not have identified associations between gene 
expression and phenotype when associations between expression and pathology may, 
in fact, be present and affecting clinical features.  
 
Longitudinal population-based studies of this size with data from pathologically 
defined case and control groups therefore present a more expensive and time-
consuming avenue of investigation that will complement the results of this study and 
present further insight into the links between gene expression and cognitive decline 
with specific pathologies.  
 
7.9.2 Retrospective analysis 
For this analysis, gene expression was quantified at year 9 of longitudinal study after 
individuals had undergone significant cognitive decline. It can confidently be 
122 
concluded, therefore, that there are no moderately large peripheral leukocyte 
expression markers of cognitive decline progression in our cohort, and that there are 
no moderately large expression markers of cognitive decline risk that are stable 
enough to be evident once functional change has become clinically apparent. 
However, as expression was measured years (perhaps decades) after cognitive decline 
onset in many of the participants, this study is unable to conclude whether moderately 
large biomarkers of cognitive decline risk are present before functional changes 
become apparent. Risk markers may be quantifiable at the onset of cognitive decline 
pathological change but return to normal levels once the cascade of pathological 
change has ensued. To identify those expression markers of risk in the population, high 
quality RNA samples taken prospectively from younger cognitively intact individuals 
would need to precede longitudinal assessment of cognitive decline. This poses a 
relevant question for further investigation. 
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7.10 Place within current literature 
7.10.1 Study precedent 
eQTL identification using data from gene expression microarrays has been used 
successfully to further the understanding of the biological basis for complex traits 
including Crohn’s disease (Libioulle et al., 2007; Fransen et al.; 2010) and asthma 
(Moffatt et al., 2007). Through eQTL mapping, these complex traits with non-
Mendelian heritability have been found to be influenced by multiple genetic loci 
exerting small, potentially interacting, quantitative effects on gene expression that 
shape phenotype in concert with environmental influences (Rockman and Kruglyak, 
2006). Furthermore, the combination of data from eQTL analyses and publically 
available genome-wide association studies has also been used to identify and to 
validate candidate genes involved in complex traits (Cookson et al., 2009).  
 
While genetic studies have thus far linked genetic variance to gene expression in 
complex traits, expression work has complemented these studies by investigating 
peripheral gene expression in association with phenotypically defined complex traits, 
including cognitive decline, as outlined in sections 1.4.3. This study therefore takes 
place in a field of study with good precedent for utilising and combining genome-wide 
expression data and genotype information in the study of a complex trait. By analysing 
a range of gene expression involvements in cognitive decline - from the small effects 
contributed by eQTLs and combining to implicate gene pathways, to the large effects 
that would provide a disease biomarker - this study has investigated three key aspects 
of the relationship between genome, transcriptome and phenotype in cognitive 
decline and is able, by way of its large, well-characterised cohort, to add significant 
knowledge to the investigation of genetics and gene expression in cognitive decline. 
 
7.10.2 Biomarkers for cognitive decline 
The search for a non-invasive biomarker of cognitive decline to aid early diagnostic and 
treatment decisions has stimulated investigations of peripheral blood as a site of 
potential marker identification. Studies investigating peripheral leukocyte gene 
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expression or plasma proteins associated with cognitive decline have, in general, been 
small case-control studies carried out in specifically selected research centre sub-
populations. Results from these studies indicate associations between peripheral 
inflammatory, oxidative stress and lipoprotein metabolism pathways and cognitive 
decline (see section 1.3 for more details).  
 
 Key recent findings relevant to this study include two large-scale reviews conducted 
by Rezai-Zadeh et al. (2007) and Cedazo-Minguez et al. (2010). Both reviews conclude 
that while small studies have identified multiple uses for peripheral leukocytes as 
biomarkers of dementia, later results produced by different groups fail to replicate 
initial findings, and usually produce conflicting results (Rezai-Zadeh et al., 2009, 
Cedazo-Minguez and Winblad, 2010). Rezai-Zadeh et al. conclude that studies with 
large sample sizes would be needed to tackle the question of whether peripheral 
signals are effective biomarkers for dementia, even before specific biomarkers are 
identified and verified. An additional review undertaken by Song et al. (2009) 
investigating plasma biomarkers for cognitive impairment reached the same 
conclusion: validation in large population-based studies is vital to validate any of the 
putative markers thus far identified by case-control studies (Song et al., 2009). The 
evidence provided by this large, population-based study suggests that while individual 
genes may have an association with cognitive decline, as demonstrated by previous 
groups’ work, none of these genes have more than a small effect on clinical 
phenotype. The clinical and diagnostic utility of such biomarkers in the general 
population is limited. 
 
7.10.3 Leukocyte gene expression as a viable marker of 
neuroinflammation 
Systemic inflammation has been linked in previous studies to both AD and to vascular 
dementia pathologies (Schmidt et al., 2002), and has been investigated as a marker of 
cognitive decline by other groups, sometimes with positive results (Song et al., 2009). 
In making use of peripheral blood leukocytes, this study provides good insight into the 
place of peripheral gene expression in the understanding and monitoring of cognitive 
decline in the population, in a clinically accessible and putatively relevant tissue. The 
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study made use of immune/inflammatory cells in the peripheral circulation and its 
results indicate that individuals’ peripheral inflammatory profile may well be very 
different to the neuroinflammatory profile consistently observed in patients with AD 
and vascular dementia pathology in association with demonstrable clinical cognitive 
decline (Lue et al., 2010, Rosenberg, 2009). That is, the inflammatory profile that is 
either contributory or reactive to the neuropathology inducing cognitive impairment is 
not echoed outside the central nervous system. 
 
In considering gene expression, this study concludes that blood leukocytes are not the 
cells of interest in the investigation of cognitive decline or its cortical pathology. 
Although highly attractive as easily accessible peripheral sources of systemic gene 
expression, peripheral blood leukocytes do not pose a readily useful target for 
monitoring cognitive decline.  A transcriptome-wide association study of brain gene 
expression in a similarly large and well-characterised cohort would yield important 
findings, but brain tissue is clearly wholly inappropriate for the diagnosis and 
monitoring of cognitive decline in the population. 
 
Moving forward from the results of this study, blood is not ruled out as a tissue for the 
investigation of cognitive decline. Proteomic studies by other groups present candidate 
serum proteins for validation in population-based cohorts. As blood proteins are 
produced by a number of tissues including those of the CNS prior to circulation in the 
blood, they may be the site of positive results for other groups carrying out proteomic 
studies with access and resources to investigate large numbers of cognitively 
characterised individuals. 
 
7.10.4 eQTLs in cognitive decline 
Cognitive decline is a complex trait whose heritability remains unexplained by known 
genetic variants. Those SNPs known to be associated with AD (the pathology of which 
is a predominant feature of age-related cognitive decline) have not yet been 
functionally characterised. In the recent pivotal GWA studies of AD, common coding 
variation did not explain the association between phenotype and GWAS-significant 
genomic regions (Harold et al., 2009, Lambert et al., 2009). The question of whether 
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significant functional SNPs act through different mechanisms e.g. through splicing 
regulation, or through alteration of expression abundance, therefore became a key 
point to address. 
 
7.10.4.1 Previous findings 
As contributions to the functional characterisation of AD SNPs, authors have 
performed targeted eQTL searches. Guerreiro et al. investigated CLU, the gene in 
which AD-associated SNP rs11136000 is located, using an eQTL analysis of 174 cortical 
samples (Guerreiro et al., 2010, Myers et al., 2007). The authors found that although 
CLU levels were higher in AD cases than controls, rs11136000 was not an eQTL for CLU 
or for any other genes within 250kb of the locus. The authors were careful to state that 
they had been powered to investigate only large eQTL effects in their cohort. They 
concluded that small eQTL effects could still contribute to the association with AD, 
although multiple eQTLs would be needed to drive the observed association.  
 
While Guerreiro et al. investigated eQTL function in a known SNP-phenotype 
association, Marioni et al. investigated this association for a known eQTL. The authors 
analysed genetic variance in inflammatory genes in association with assumed lifetime 
cognitive change using a large cohort from the Aspirin for Asymptomatic 
Atherosclerosis trial (Marioni et al., 2010). The authors studied 12 SNPs, one of which 
was an eQTL in IL-1β, a peripheral inflammatory gene previously found to associate 
with cognitive decline (Trompet et al., 2008). The authors produced negative results 
and identified no association between eQTL and phenotype.  
 
The limited results gleaned from these two eQTL investigations imply that many 
unpublished negative results may have been generated by eQTL analyses in cognitive 
decline. However, limitations of the two investigations allow room for progression in 
further eQTL studies, and the hope that positive results will be generated by different 
methodologies. Guerreiro et al. investigated a pathologically defined phenotype, 
rather than a functional phenotype, and they investigated only a single SNP for the 
purposes of their study. The study conducted by Marioni et al. also had methodological 
features making it an uncertain source of conclusive data for this field. Firstly, the eQTL 
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investigated by the group was chosen for analysis because of its location in a putatively 
significant gene, rather than for a known association with inflammatory gene 
expression abundance. Secondly, different cognitive assessments were performed by 
participants at baseline and follow-up. Their measure of lifetime cognitive change was 
inferred from the combination of these results, rather than from change to a single 
performance measure over time. Two benefits of the current study within the field of 
genetic analysis of cognitive decline were therefore that 1) the SNPs investigated were 
known to have a robust association with a phenotype of cognitive decline and 2) the 
cognitive decline phenotype was derived from repeated measures of the same 
cognitive test, simplifying trajectory monitoring and producing a reliable measure. In 
addition, the use of genotyped peripheral blood samples, rather than the cortical 
samples used by Guerreiro et al., allowed the use of data from a large cohort of 
functionally defined individuals. 
 
7.10.4.2 eQTLs may act differently in different tissues 
One key feature of genetic influence on gene expression is that it can be tissue-
specific. Heinzen et al. (2008) investigated SNPs associated with alternative splicing in 
cortical and peripheral blood mononuclear cells, and found that less than 50% of 
implicated SNPs showed effects in both tissue types (Heinzen et al., 2008). Tissue 
specificity has also been found to affect cis- and trans-eQTL activity (Lee et al., 2009). 
Different epigenetic factors active in different tissue types could have a significant 
effect on gene expression beyond that quantified by this study. The need for cortical 
eQTL analysis performance is re-highlighted by this consideration, but the need to 
investigate peripheral blood as a marker tissue remains crucial in the study of 
inaccessible cortical complex traits. 
 
7.10.5 Overall insight gained 
The need to examine complex traits from genetic, transcriptomic, pathological and 
whole-organism perspectives has been outlined in section 7.1. Only a combined 
understanding of each interacting aspect can lead to improvements in the diagnosis 
and treatment of complex multifactorial diseases, including cancers (Schwaenen et al., 
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2009, Weigelt et al., 2009), and autoimmune disorders (Fransen et al., 2010, Moffatt et 
al., 2007). This study made use of genetic, transcriptomic and phenotypic data to 
analyse links between the three. In doing so, the study has provided insight into 
functional genetic influences over gene expression in cognitive decline, the gene 
pathways functionally involved in cognitive decline, and the value of using peripheral 
expression data to investigate cognitive decline progression. The study has established 
that peripheral inflammation is not a key component of cognitive decline or cognitive 
impairment in humans, and also that an association exists between peripheral CCR2 
expression and cognitive performance, validating the use of the CCR2-knockout mouse 
as a relevant animal model of human cognitive impairment. 
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7.11 Further work 
7.11.1 Replication of CCR2 association 
CCR2 has received attention as an inflammatory mediator in mouse models of 
Alzheimer’s-like pathology and cognitive performance (El Khoury et al., 2007, Naert 
and Rivest, 2011), but this study presents the first evidence of an association between 
expression of CCR2 and cognitive performance in humans. Replication experiments in a 
further population-based cohort study are crucial to the validation of the finding and 
its potential relevance to the study of cognitive decline. Validation of this study’s 
findings using the gold-standard qRT-PCR method of expression quantification is 
currently being conducted by Dr. Harries’ lab. 
 
7.11.1 Functional characterisation of rs744373 
An immediate follow-up study resulting from this work could be the functional 
characterisation of eQTLs rs744373 and rs157580. In this cohort, BIN1 and PVRL2 do 
not have significant associations with cognitive decline, but it has already been 
outlined that associations between eQTL-dependent expression and phenotype are 
unlikely to be large or to achieve statistical significance in studies of pathologically 
variant populations.  
 
rs744373 and its proxy rs730482 are both intergenic, upstream of BIN1. A useful initial 
functional characterization would involve the analysis of enhancer or silencer regions 
at the two loci. Initial in silico transcription factor binding analysis performed using the 
SABiosciences Decipherment of DNA elements facility (DECODE), making use of the 
University of California Santa Cruz Genome Browser and the SABiosciences Text Mining 
Application (http://www.sabiosciences.com/chipqpcrsearch.php?app=TFBS), indicates 
that no transcription factors for BIN1 are currently known to bind to the region 
surrounding rs744373 or rs730482. Functional analysis of the eQTL could therefore 
comprise development of a luciferase reporter vector to analyse putative transcription 
factor binding activity at rs744373 in individuals with different genotypes. Multiple 
experiments investigating individual transcription factors’ binding to the region would 
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be necessary for an adequate functional analysis of the region surrounding rs744373 
as a novel response element.  
 
The investigation of the SNP in TOMM40 for PVRL2 has already been discussed in 
section 7.7.4 
 
7.11.2 Prospective study 
As described in section 7.9.2, the results from a retrospective study of gene expression 
and cognitive decline may be very different to the results generated by a prospective 
study. Prospective environmental, physical and biological studies of cognitive decline 
have all added to current knowledge about the condition (for an overview, see 
(Daviglus et al., 2010)). Accordingly, a prospective population-based study analyzing 
gene expression in a large cohort of young, cognitively intact individuals for whom 
cognitive change is subsequently plotted over more than a decade would present 
useful results. Both confirmation of this study’s negative findings, and the potential 
generation of candidate biomarker genes, would be important findings in a field 
where, to date, few risk predictors have been identified. A difficulty with the proposed 
study would be that the pathology, and even minor clinical manifestations, of cognitive 
decline, may begin to develop when adults are in their late 40s; Salthouse suggests 
that the processes may even begin late in the third decade (Salthouse, 2009). Attrition 
rates from a prospective cohort study over the potential 4 decades necessary to gain 
truly representative data of cognitive health before decline may make such a large 
study impractical.  
 
7.11.3 Epigenetics of cognitive decline 
An additional regulator of gene expression important in complex traits is epigenetic 
regulation, involving histone acetylation, phosphorylation and methylation, and DNA 
methylation. Decreased DNA methylation with advancing age is genome-wide (Liu et 
al., 2009) but histone modification impacts on telomere regulation (Blasco, 2007), and 
on chromatin plasticity and remodeling (Penner et al., 2010): changes which are 
associated with age and which impact on memory formation (Roth and Sweatt, 2009). 
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Recently, authors have argued that deregulation of epigenetic modification may drive 
memory disturbances in the ageing brain (Penner et al., 2010, Peleg et al., 2010). A 
genome-wide histone modification profile and DNA methylation analysis could be 
conducted on DNA currently held by this group across the InCHIANTI cohort, posing a 
suitable next step to complement the range of genetic and transcriptomic insights 
provided by the experiments conducted as part of this study. 
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7.12 Conclusions 
This population-based study has suggested that peripheral inflammatory processes do 
not play a significant role in cognitive decline. Only one inflammatory transcript (CCR2) 
was significantly associated with cognitive impairment at genome-wide analysis. The 
CCR2 knockout mouse has been shown to have Alzheimer’s-like pathology; results of 
this study indicate that the mouse model may have relevance for the human 
population.  
 
Associations were identified between GWAS-significant SNPs for AD and expression of 
local genes, indicating that the SNPs function as eQTLs. Associations between 
expression of eQTL-targeted genes and cognitive decline were insignificant in the 
cohort, indicating that any true effects of these eQTLs on phenotype are probably 
small.  
133 
Appendix 
 
Table S1 Inflammatory gene pathways and probes. The 44 gene pathways selected to 
be part of the inflammatory subset analysis are given. Also given are the number of 
annotated probes in each pathway, the number of these probes present on the 
Illumina Human_HT12 v3 microarray which passed QC in this cohort and the 
percentage of pathway probes therefore available to be quantified in this cohort 
 
Gene pathway 
N annotated 
probes 
N probes 
held 
% 
Activation of immune response 17 12 70.6 
Acute inflammatory response 11 5 45.5 
Adaptive immune response 25 14 56.0 
Adaptive immune response go 
0002460 
24 13 54.2 
Antigen binding 28 15 53.6 
B cell activation 19 13 68.4 
Chemokine activity 42 15 35.7 
Cytokine activity 111 38 34.2 
Cytokine and chemokine mediated 
signaling pathway 
23 13 56.5 
Cytokine binding 46 33 71.7 
Cytokine biosynthetic process 40 24 60.0 
Cytokine metabolic process 41 25 61.0 
Cytokine production 72 46 63.9 
Cytokine secretion 18 10 55.6 
Cytokinesis 19 8 42.1 
Humoral immune response 31 17 54.8 
Immune effector process 38 22 57.9 
Immune response 232 149 64.2 
Immune system development 80 52 65.0 
Immune system process 326 218 66.9 
Immunological synapse 11 9 81.8 
Inflammatory response 124 81 65.3 
Innate immune response 23 8 34.8 
Interleukin 1 secretion 10 8 80.0 
Jak stat cascade 31 23 74.2 
Jnk cascade 47 32 68.1 
Leukocyte activation 67 42 62.7 
Lymphocyte activation 60 38 63.3 
Negative regulation of cytokine 
biosynthetic process 
11 5 45.5 
Negative regulation of immune 
system process 
14 7 50.0 
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Nuclear speck 11 7 63.6 
Positive regulation of cytokine 
biosynthetic process 
24 16 66.7 
Positive regulation of cytokine 
production 
15 11 73.3 
Positive regulation of cytokine 
secretion 
10 6 60.0 
Positive regulation of immune 
response 
29 16 55.2 
Positive regulation of immune system 
process 
51 31 60.8 
Production of molecular mediator of 
immune response 
13 7 53.8 
Regulation of cytokine biosynthetic 
process 
37 22 59.5 
Regulation of cytokine production 25 16 64.0 
Regulation of cytokine secretion 16 8 50.0 
Regulation of immune effector 
process 
15 9 60.0 
Regulation of immune response 33 16 48.5 
Regulation of immune system process 67 41 61.2 
T cell activation 44 27 61.4 
 2031 1228 
Mean = 
59% 
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